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Abstract 
Two experiments were conducted to determine the practicality of utilizing follicular 
ablation (FA) in mares. Experiment 1 investigated the efficacy of FA as a technique for ovulation 
synchronization. Twenty non-pregnant mares were assigned to the ablation (FA) or P+E 
(progesterone + estradiol) treatment (n = 10/treatment). In the FA treatment, follicles > 10 mm 
were ablated (d 1) and mares were administered PGF2α on d 5. Mares received hCG d 11 and 
ovaries were monitored via transrectal ultrasound until ovulation. The P+E mares received 150 
mg P + 10 mg E for 10 d with concurrent PGF2α administration d 10. Ultrasound monitoring 
began on d 15 continuing until ovulation. On d 18, P+E mares received hCG. Interval from 
initiation of treatments to ovulation and interval from hCG administration to ovulation was 
reduced (P < 0.01) in response to FA. Ablation may be an acceptable, non-steroidal alternative 
for synchronization of ovulation and has the ability to shorten the interval from treatment to 
ovulation. 
The objective of Experiment 2 was to determine if FA could prolong the postpartum 
interval to ovulation. Eighteen postpartum mares were assigned to receive FA (n = 10) or be 
untreated controls (CON, n = 8). In FA mares, follicles > 10 mm were ablated on d 6 postpartum. 
Mares were administered PGF2α on d 11 and monitored via transrectal ultrasound until ovulation. 
When a follicle ≥ 35 mm was detected, mares received hCG. The CON mares were evaluated via 
ultrasound beginning on d 4 postpartum until a follicle ≥ 35 mm was detected. Mares were then 
administered hCG and ovaries were monitored until ovulation. Compared with controls, ablation 
prolonged (P < 0.01) the interval from foaling to ovulation and could be utilized to optimize the 
timing of breeding to improve postpartum conception rates.  
  
Existing research is limited on foal bone development in response to peri-partum 
maternal supplementation of n-3 fatty acids. Experiment 3 investigated the effect of maternal n-3 
fatty acid supplementation on neonatal bone metabolism and mare reproductive traits. Seventeen 
pregnant stock-type mares were assigned to either of two treatment diets: Control (CON; n = 8, 
concentrate with no fat supplementation) or fat-supplemented (FS; n = 9, concentrate plus 
Gromega™, which provided 13.475 g of eicosapentaenoic acid (EPA) and 11.162 g of 
docosahexaenoic acid (DHA) per day). Treatment began 8 wk before expected foaling date. 
Blood samples were collected every other week throughout the trial and additional sampling 
occurred once a follicle > 30 mm was first detected post-foaling and continued until d 5 post-
ovulation. Serum was analyzed for progesterone (P4) and insulin-like growth factor-1 (IGF-1). 
Follicular activity was monitored via transrectal ultrasound from d 4 postpartum until ovulation. 
Foal blood collection occurred weekly for 8 wk. At 2 and 4 wk of age, synovial fluid (SF) was 
collected and submitted for cytology. Plasma and SF were evaluated for markers of bone 
metabolism. Plasma DHA and EPA were increased (P < 0.05) in the FS mares and their foals. 
No differences (P > 0.05) were detected in gestation length, concentrations of IGF-1 or P4, or the 
postpartum interval to ovulation. In addition, no differences were detected in foal plasma 
metabolites, SF prostaglandin E2, or osteocalcin. Compared with CON, SF carboxy-terminal 
cross-linked telopeptide of type 1 collagen (ICTP) was greater (P < 0.05) in the FS treatment at 
wk 4 and SF total protein was greater (P < 0.05) at both time points in the FS treatment. A 
correlation was detected (P < 0.05) between synovial and plasma ICTP concentrations (r = 0.49). 
Maternal n-3 supplementation did not affect mare reproductive traits and had a minimal effect on 
foal bone metabolism in healthy foals fed to meet their requirements.  
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Abstract 
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ablation (FA) in mares. Experiment 1 investigated the efficacy of FA as a technique for ovulation 
synchronization. Twenty non-pregnant mares were assigned to the ablation (FA) or P+E 
(progesterone + estradiol) treatment (n = 10/treatment). In the FA treatment, follicles > 10 mm 
were ablated (d 1) and mares were administered PGF2α on d 5. Mares received hCG d 11 and 
ovaries were monitored via transrectal ultrasound until ovulation. The P+E mares received 150 
mg P + 10 mg E for 10 d with concurrent PGF2α administration d 10. Ultrasound monitoring 
began on d 15 continuing until ovulation. On d 18, P+E mares received hCG. Interval from 
initiation of treatments to ovulation and interval from hCG administration to ovulation was 
reduced (P < 0.01) in response to FA. Ablation may be an acceptable, non-steroidal alternative 
for synchronization of ovulation and has the ability to shorten the interval from treatment to 
ovulation. 
The objective of Experiment 2 was to determine if FA could prolong the postpartum 
interval to ovulation. Eighteen postpartum mares were assigned to receive FA (n = 10) or be 
untreated controls (CON, n = 8). In FA mares, follicles > 10 mm were ablated on d 6 postpartum. 
Mares were administered PGF2α on d 11 and monitored via transrectal ultrasound until ovulation. 
When a follicle ≥ 35 mm was detected, mares received hCG. The CON mares were evaluated via 
ultrasound beginning on d 4 postpartum until a follicle ≥ 35 mm was detected. Mares were then 
administered hCG and ovaries were monitored until ovulation. Compared with controls, ablation 
prolonged (P < 0.01) the interval from foaling to ovulation and could be utilized to optimize the 
timing of breeding to improve postpartum conception rates.  
  
Existing research is limited on foal bone development in response to peri-partum 
maternal supplementation of n-3 fatty acids. Experiment 3 investigated the effect of maternal n-3 
fatty acid supplementation on neonatal bone metabolism and mare reproductive traits. Seventeen 
pregnant stock-type mares were assigned to either of two treatment diets: Control (CON; n = 8, 
concentrate with no fat supplementation) or fat-supplemented (FS; n = 9, concentrate plus 
Gromega™, which provided 13.475 g of eicosapentaenoic acid (EPA) and 11.162 g of 
docosahexaenoic acid (DHA) per day). Treatment began 8 wk before expected foaling date. 
Blood samples were collected every other week throughout the trial and additional sampling 
occurred once a follicle > 30 mm was first detected post-foaling and continued until d 5 post-
ovulation. Serum was analyzed for progesterone (P4) and insulin-like growth factor-1 (IGF-1). 
Follicular activity was monitored via transrectal ultrasound from d 4 postpartum until ovulation. 
Foal blood collection occurred weekly for 8 wk. At 2 and 4 wk of age, synovial fluid (SF) was 
collected and submitted for cytology. Plasma and SF were evaluated for markers of bone 
metabolism. Plasma DHA and EPA were increased (P < 0.05) in the FS mares and their foals. 
No differences (P > 0.05) were detected in gestation length, concentrations of IGF-1 or P4, or the 
postpartum interval to ovulation. In addition, no differences were detected in foal plasma 
metabolites, SF prostaglandin E2, or osteocalcin. Compared with CON, SF carboxy-terminal 
cross-linked telopeptide of type 1 collagen (ICTP) was greater (P < 0.05) in the FS treatment at 
wk 4 and SF total protein was greater (P < 0.05) at both time points in the FS treatment. A 
correlation was detected (P < 0.05) between synovial and plasma ICTP concentrations (r = 0.49). 
Maternal n-3 supplementation did not affect mare reproductive traits and had a minimal effect on 
foal bone metabolism in healthy foals fed to meet their requirements.  
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1 
Chapter 1 - Review of Current Literature for Experiments 1 and 2 
 Reproductive Hormones in the Cycling Mare 
Many different hormones from a variety of sources are responsible for control of the 
mare’s reproductive cycle. Control of the estrous cycle in the mare is a concerted effort of the 
intricate hypothalamic-pituitary-gonadal axis (Senger, 2005). The hypothalamus, pituitary and 
gonads are involved in the regulation of many bodily functions, but their primary collective 
focus is the complex control of reproductive function. These separate endocrine glands act as a 
single unit through the associated negative and positive feedback effects connected with the 
various hormones they produce. The hypothalamus is the key regulator of this axis and serves as 
a link between the nervous and endocrine systems. The hypothalamus releases neurohormones 
that act on the pituitary that induce release of gonadotropins that target specific sites on the 
gonads. Stimulation of gonads results in secretion of hormones that then positively or negatively 
affect hormone production from the hypothalamus and pituitary (Senger, 2005). The following 
review will cover the primary hormones involved in the regulation of the estrous cycle of the 
mare.  
 Gonadotropin-Releasing Hormone  
Gonadotropin-releasing hormone (GnRH) is a neuro-decapeptide highly conserved across 
species (Ginther, 1992). It is produced by neurosecretory cells located in the hypothalamus 
(Senger, 2005). The pineal gland acts as the regulator between sensory inputs and the 
hypothalamic-pituitary axis and the pulsatile release of GnRH from the hypothalamus. In the 
mare during the normal period of seasonal cyclicity, melatonin secretion from the pineal gland is 
suppressed because of the extended photoperiod, thus allowing constant pulses of GnRH to be 
released from the hypothalamus (Strauss et al., 1979). Release of GnRH from the hypothalamus 
2 
occurs either from the collection of neurons that make up the arcuate and ventromedial nuclei 
responsible for the tonic releases of GnRH or the superchiasmatic nucleus, which is referred to as 
the surge center (Senger, 2005). These nuclei reside in the medial basal hypothalamus. The 
axons of the neurosecretory cells reach into the periventricular space in the median eminence and 
GnRH is contained within vesicles in the median eminence (Strauss et al., 1979). Release of 
GnRH from these vesicles occurs in a pulsatile manner. Hypothalamic neurons communicate 
with the anterior pituitary through a specialized and localized blood circulation system referred 
to as the hypothalamo-hypophyseal portal system (Senger, 2005). Minute concentrations of 
GnRH are necessary to provoke an effect on gonadotroph cells. This results from the specialized 
circulation in close proximity between the hypothalamus and the anterior pituitary, which GnRH 
stimulates its effect before dilution in systemic circulation. The 5- to 10-min half-life of GnRH 
(Conn et al., 1987), coupled with the restriction of its action in the hypothalamo-hypophyseal 
portal system before going into systemic circulation, makes it virtually undetectable in the 
peripheral blood supply (Ginther, 1992). The stage of the mare’s estrous cycle influences from 
which hypothalamic center GnRH is release and at what frequency. Anestrous mares secrete 
GnRH from the tonic centers in a low amplitude pulsatile manner with long periods of time 
between releases. Anestrous mares may experience a single release every 8 h that will increase to 
four pulses per 8 h as mares transition to normal estrous activity (Fitzgerald et al., 1983). In 
normal, cycling mares, GnRH is secreted continuously with additional pulses occurring as 
infrequently as once daily in diestrous mares (Alexander et al., 1990). Pulsatile frequency 
increases to once every 1 to 2 h in mares in the peri-ovulatory period, and occurs as frequently as 
twice per hour in mares at ovulation (Ginther, 1992). When threshold circulating levels of 
estrogen (E) are reached in the absence of progesterone (P4), the increased pulse frequency of 
3 
GnRH stimulates a similar increased pulse frequency of LH (luteinizing hormone). The LH 
pulses become too frequent for complete removal of LH from circulation prior to the next release 
and the LH concentration builds up to threshold levels. Once threshold LH levels are reached, 
the cascade of events leading up to ovulation is initiated. Increased GnRH stimulates the 
production and secretion of gonadotropins from the anterior pituitary and has a controlling 
influence over these gonadotropin hormones. Actions of these gonadotropins subsequently 
control other reproductive hormones (Senger, 2005). The classical form of GnRH1 is considered 
the major hormone regulator of reproduction; however, recent research has identified a second 
isoform, GnRH2 and its associated receptor, that is not involved in gonadotropin stimulation in 
the pituitary (Desaulniers et al., 2017). 
 Gonadotropins 
Primary gonadotropins produced by gonadotroph cells in the anterior lobe of the pituitary 
are follicle stimulating hormone (FSH) and LH. These gonadotropins are primarily responsible 
for folliculogenesis and steroid production (Senger, 2005). Both LH and FSH are glycoproteins 
consisting of two subunits. The alpha subunit of both of these hormones is conserved (Stewart et 
al., 1987), whereas differing beta subunits give each glycoprotein high specificity and function 
(Sherwood and McShan, 1977). Secretion of GnRH from the hypothalamus through the 
hypothalamo-hypophyseal portal system causes upregulation of both FSH and LH production 
and secretion in the anterior pituitary. Both FSH and LH are similarly upregulated by GnRH but 
are also controlled by other hormones, such as inhibin and E, that differentially influence either 
FSH or LH production or activity (Ginther, 1992). During the estrous cycle, FSH is generally 
regarded to be released in a bi-modal wave pattern (Burns and Douglas, 1981) with basal and 
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pulsatile secretion are controlled by dual mechanisms (Padmanabhan et al., 1997). Pulsatile 
releases of LH are attributed to pulsatile releases of GnRH (Clayton and Royston, 1989).  
The target tissue for FSH is the granulosa cell in the antrum of a follicle (Senger, 2005). 
Binding of FSH occurs on plasma membrane bound receptors located on the granulosa cell 
membranes (Ulloa-Aguirre et al., 2013). Increased FSH concentrations stimulate growth and 
recruitment of a cohort of immature follicles and maturation of the primordial germ cell. As FSH 
rises and stimulates follicular growth, an associated rise in inhibin from the dominant follicle 
downregulates the secretion of FSH at the level of the anterior pituitary (Donadeu and Pedersen, 
2008). Only more mature follicles can still respond to the decreasing concentrations of FSH, so 
only the most mature follicle(s) is selected to become dominant, with the more immature 
follicles no longer able to be rescued by declining concentrations of FSH and therefore undergo 
atresia. If the dominant follicle in the preovulatory wave is ablated, other smaller follicles may 
go on to become dominant and ovulate, demonstrating that all follicles have the ability to reach 
dominance (Ginther et al., 2003).  
The target for LH is the plasma membrane receptor located on the theca interna cells of 
the antral follicle and the luteal cells of the corpus luteum (Senger, 2005). Release of LH occurs 
in a pulsatile fashion synchronous with GnRH pulse secretions (Clayton and Royston, 1989) with 
a half-life lasting approximately 1 h (Cole and Hart, 1930). When LH concentrations are elevated 
before ovulation, pulse frequency is too rapid to detect in systemic circulation (Fitzegerald et al., 
1983). Concentrations of LH show a long, slow rise, peaking before ovulation (Irvine and 
Alexander, 1994) and reaching maximum concentrations 1 to 2 d post-ovulation followed by a 
rapid decline during diestrus, which is defined as the period of sustained luteal function and 
maximum P4 production (Palmer, 1978). Circulating concentrations of LH during anestrus are 
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similar to concentrations during diestrus (Garcia and Ginther, 1976). The LH surge initiates the 
ovulatory cascade and subsequent formation of the corpus luteum (CL) and P4 production by the 
CL. Circulating LH also works in concert with FSH for final follicular maturation and ovulation 
(Senger, 2005). 
 Steroid Hormones 
Steroid hormones are synthesized from cholesterol by a series of complex enzymatic 
processes (Senger, 2005). Steroid hormones produced in the mare include testosterone (T), 
estrogens, and progestins (Ginther, 1992). Estradiol-17β (E2) is the estrogen of interest in the 
estrous mare and is produced from the enzymatic conversion of testosterone by the granulosa 
cells of an antral follicle under the influence of FSH and LH (Short, 1961). Target tissues of E2 
include the hypothalamus, where it has a positive feedback effect on the release of GnRH and 
enhances the response of LH to GnRH, and also tissue throughout the reproductive tract of the 
mare, where it increases secretory activity and enhances uterine motility (Thompson et al., 
1991). Circulating E2 causes decreased uterine tone and relaxation of the cervix and is also 
responsible for inducing sexual behavior and receptivity to mating (Senger, 2005). The day 
before follicular deviation, E2 concentrations begin to rise and reach peak concentrations before 
ovulation (Ginther et al., 2001). Estrogen concentrations rise concurrently with LH (Noden et al., 
1978). Increased FSH also contributes to increased production of E2 at the level of the dominant 
follicle (Senger, 2005). 
Progesterone is the progestin of interest in the non-pregnant mare and is the primary 
steroid hormone during diestrus. Following ovulation, granulosa and theca cells within the 
evacuated follicle luteinize and begin secreting P4. Production of P4 increases during the first 24 
to 36 h post-ovulation (Short, 1961), reaching peak values of 4-22 ng/mL by 5 to 7 d post-
6 
ovulation (Ginther, 2009). Target tissue for P4 includes the uterus and cervix of the reproductive 
tract and neuropeptides at the level of the hypothalamus. Circulating P4 is responsible for 
increased uterine and cervical tone in the diestrous mare (Ginther, 1992). In addition, P4, in 
concert with decreased E2, suppresses behavioral estrus and receptivity to a stallion. In addition, 
P4 serves as a strong negative feedback on GnRH release from the hypothalamus; therefore, also 
exerting a strong negative feedback on LH. Concentrations of P4 rise as LH decreases and fall as 
LH increases (Noden et al., 1978).  
 Additional Hormones of Reproductive Interest 
Other hormones of reproductive interest that are neither categorized as gonadotropins or 
steroid hormones are involved in regulation of the estrous cycle in the mare. Inhibin is a 
glycoprotein produced by the granulosa cells in antral follicles on the ovary. As a dominant 
follicle approaches ovulation, increased synthesis of inhibin by these cells occurs (Ginther, 
1992). The target of inhibin is the anterior lobe of the pituitary where it inhibits FSH secretion 
but has a minimal effect on LH (DeJong, 1987). Circulating concentrations of inhibin are 
inversely related to circulating FSH and the period of greatest circulating inhibin occurs at 
ovulation, rapidly declining post-ovulation (Bergfelt et al., 1991). 
Prostaglandins are lipids that consist of 20-carbon fatty acids and are derived from 
arachidonic acid (Pike, 1971). Many different types of prostaglandins are involved in a wide 
array of physiological processes (Senger, 2005). Two prostaglandins of particular reproductive 
interest are prostaglandin F2α (PGF2α) and prostaglandin E2 (PGE2). These prostaglandins are 
produced by the ovary and uterine endometrium in the non-pregnant mare. The mode of action of 
prostaglandins is generally via an autocrine or paracrine function (Ginther, 1992). One target for 
PGF2α is the CL where it initiates luteolysis at approximately d 14 of the estrous cycle if the 
7 
mare is not pregnant (Ginther, 2009). Increased PGF2α also promotes uterine contractions and 
increases contractions of ovarian smooth muscle to increase follicular pressure before ovulation. 
With regard to its role in ovulation, PGE2, in addition to histamines produced by the ovary and 
uterus, stimulate increased localized blood flow to the ovary including the dominant follicle, 
thereby increasing both edema and intra-follicular pressure before ovulation. Circulating PGE2 is 
also involved in remodeling of the evacuated follicle to form the CL and stimulating secretion of 
P4 by the CL by inducing LH receptors in the CL, leading to LH-induced P4 production 
(Niringiyumukiza et al., 2018).  
 Estrous Cycle of the Mare 
Mares are seasonally polyestrous, which is characterized by regular estrous cycles during 
late spring, summer, and early fall followed by cycle quiescence during winter months. 
Quiescence is bracketed by both a spring or vernal transition and a fall transition period. During 
the fall transition, mares generally experience erratic estrous cycles and finally cease cycling and 
transition to anestrus during late fall and winter months (King, 2011). Following a period of 
winter anestrus, mares will undergo another transition in the spring months. The increase in day 
length and exposure to increasing amounts of light stimulates the pineal gland of the mare 
resulting in a reduced melatonin production. External light stimulus is transmitted from the 
superchiasmatic nucleus to the paraventricular nucleus (PVN), then from the PVN to the superior 
cervical ganglia and finally to the pineal gland. Melatonin production in the pineal cells 
decreases in long-day breeders in response to increased daily light duration (Clifton and Steiner, 
2009). Reduced melatonin decreases its suppressive effect on GnRH secretion and release from 
the hypothalamus. Release of increased amounts of GnRH stimulates both FSH and LH 
production, which are responsible for recruiting and selecting a dominant follicle to grow and 
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ovulate for the first ovulation of the season. After transitioning to normal cyclic activity, a mare 
will continue to cycle every 21 d (± 3 d) until she enters the fall transition followed by seasonal 
anestrus during late fall and winter months (Ginther, 1992).  
 Follicular Phase 
A typical 21-d estrous cycle is illustrated in Fig. 1.1. It is categorized by two distinct 
phases based on the dominant steroid hormone influencing the cycle during each phase. The 
follicular phase includes the period of time from CL regression to ovulation, and consists of the 
stages of proestrus and estrus. This phase accounts for approximately 20% of the estrous cycle 
and lasts 7.7 ± 2.9 d in mares (Ginther et al., 1972). During the follicular phase, P4 declines 
rapidly during luteolysis, which upregulates gonadotropin release from the hypothalamus, 
followed by an increase in FSH and LH release from the anterior pituitary to stimulate follicular 
growth and maturation of the preovulatory follicle in preparation for ovulation (Alexander and 
Irvine, 2011). Increased production of E2 begins 6 to 8 d before ovulation, reaching peak 
concentrations 2 d before ovulation (Makawiti et al., 1983). Increased E2 during the follicular 
phase, in the absence of negative inhibition from P4, stimulates sexual behavior and receptivity, 
and has a negative feedback effect on FSH release (Senger, 2005). Release of FSH is also 
negatively impacted by increased inhibin production from the dominant follicle. Increased E2 
concentrations also have a positive feedback effect on GnRH and LH, initiating the preovulatory 
surge of these hormones, which initiates the ovulatory cascade. That cascade will be reviewed in 
a subsequent section.  
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Figure 1.1 Circulating hormones during the estrous cycle of the mare – Adapted from Taylor-
MacAllister and Freeman. 
 
 Luteal Phase 
Post-ovulation, the estrous cycle shifts from the follicular phase to the luteal phase which 
consists of the stages of metestrus and diestrus. The luteal phase lasts 15.8 ± 2.5 d and accounts 
for approximately 80% of the duration of the estrous cycle (Ginther et al., 1972). Metestrus is 
characterized by CL formation because of luteinization of the granulosa and theca cells from the 
now evacuated dominant follicle and the switch from E2 to P4 dominance, with increasing 
amounts of P4 now being produced by the CL. Progesterone secretion rises rapidly following 
ovulation, reaching peak concentrations by 8 d post-ovulation (Lofstedt, 2011). Diestrus is 
characterized by sustained luteal P4 production and maximal luteal function and generally lasts 
15 ± 3 d (Loftstedt, 2011). The release of PGF2α from the uterine endometrium at approximately 
d 14 after ovulation is responsible for luteolysis. Luteolysis causes a drastic and immediate drop 
in circulating P4, removing the negative feedback for GnRH secretion and the inhibition of 
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behavioral estrus. Luteolysis terminates diestrus and the cycle is shifted back to the follicular 
phase as a new dominant follicle is matured and prepared for ovulation (Senger, 2005).  
 Follicular Development in the Mare 
Folliculogenesis can be described as the process by which immature follicles develop into 
more advanced follicles and are either selected to become candidates for ovulation or undergo 
atresia (Senger, 2005). Follicular waves may be classified as major or minor, with major waves 
being the only ones that can produce dominant follicles that go on to ovulate (Donadeu and 
Pedersen, 2008). For this review, the focus will be on the major follicular wave. There are 
several major periods that occur during folliculogenesis and they can be defined as recruitment, 
emergence, selection, deviation and dominance (Evans, 2003; Donadeu and Pedersen, 2008). 
Some researchers characterize recruitment and emergence as a single phase (Ginther et al., 1996) 
but others have defined recruitment as a separate phase defined by the growth of follicles that 
have become dependent on gonadotropin support (Driancourt, 2001). Emergence is characterized 
as the day when a cohort of follicles develops an antrum and are able to be visualized using 
ultrasonography (Evans, 2003). Generally, emergence in the horse is defined as the time period 
when a follicle reaches 6 mm (Ginther et al., 2003). Once the cohort of follicles emerges, 
common growth of these follicles is observed at a rate of 2 to 3 mm per day (Donadeu and 
Pedersen, 2008) for approximately 6 d (Ginther, 2000). Reduction in the number of follicles in 
the cohort is described as selection of the dominant follicle. At the end of selection, deviation of 
diameter of the largest and second largest follicle is observed. Deviation is generally 
characterized as beginning 7 d before ovulation, when a follicle reaches 22 mm in diameter, or 
both (Ginther, 2003). Growth of the selected follicle remains constant and the subordinate 
follicles arrest and undergo atresia. The single follicle now achieves dominance and will grow to 
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approximately 35 to 45 mm before ovulation under the influence of E2 and LH (Donadeu and 
Pedersen, 2008). 
 Ovulation in the Mare 
Unique to the mare, ovulation is restricted to the ovulatory fossa limiting them to 
ovulation of a single dominant follicle from the ovary at a given time. Double ovulation, or the 
ovulation of a follicle from each ovary, either synchronously or asynchronously, is not 
uncommon, but would not be classified as a normal occurrence. Although not common, a mare 
also may experience asynchronous ovulations of multiple follicles from the same ovary. A 
primary double ovulation is generally characterized as ovulations that are 1 to 2 d apart (Ginther, 
1992). Rate of double ovulations may be affected by several factors, such as breed and previous 
history of multiple ovulations, and has been reported to range from 8 to 25% (Ginther, 1986). 
Ovulation is characterized as a cascade of events including a complex regulatory system 
under hormonal control.  As previously described, threshold concentrations of E2 produced by 
the dominant follicle positively influence the surge center of the hypothalamus, initiating the 
release of large quantities of GnRH in a preovulatory surge. The surge of GnRH initiates a surge 
release of LH (at greater than 10 times basal concentrations) from the anterior pituitary. 
Dominant follicles also produce angiogenic factors and histamines that promote generation of 
new blood vessels surrounding the follicle to increase localized blood flow (Senger, 2005). 
Increased PGE2, upregulated by the preovulatory surge of LH, stimulates hyperemia to the ovary 
and in particular the dominant follicle. Hyperemia from angiogenesis and vasodilation provide 
the dominant follicle with the hormonal stimulus and metabolites necessary for final maturation 
and ovulation. Circulating PGE2 also promotes increased edema that contributes to increased 
intrafollicular pressure eventually involved in antrum rupture. Another prostaglandin, PGF2α is 
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synthesized and released locally by the ovary to stimulate contractions of ovarian smooth muscle 
that also contributes to increased intrafollicular pressure. Circulating PGF2α also stimulates 
release of lysosomal enzymes from granulosa cells that are responsible for connective tissue 
degradation, thereby weakening the follicular wall (Murdoch and Gottsch, 2003). Within the 
dominant follicle, the shift from E2 production by granulosa cells to small amounts of P4 from 
theca interna cells upregulates the production and release of collagenases that break down 
collagen and further weakens cell membranes. Increased follicular pressure and follicular wall 
weakening occur. Visualization of the pre-ovulatory follicle by ultrasound imaging generally 
shows a softening of the follicle and irregularity in shape (Ginther, 1986). Breakdown of the 
follicular wall eventually leads to follicular rupture and collapse which characterizes ovulation. 
The oocyte is released from the follicle through the ovulatory fossa to enter the oviduct (Senger, 
2005).  
Once ovulation has occurred, a corpus hemorrhagicum (CH) forms briefly at the site of 
the evacuated follicle. The CH develops because of localized hemorrhaging from small blood 
vessels rupturing during and following ovulation. The same steroidogenic cells in the dominant 
follicle that are involved in the production of T and E2, and a small amount of P4, are also 
responsible for steroidogenesis of P4 during the luteal phase. Circulating LH stimulates 
luteinization of the evacuated follicle with theca interna cells transitioning to small luteal cells 
and granulosa cells transitioning to large luteal cells. Both of these cell types are responsible for 
P4 production, which will increase rapidly over the next several days and reach peak 
concentrations 5 to 6 d post-ovulation (Senger, 2005). 
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 Ovulation Synchronization in the Mare 
Ovulation synchronization in the mare is a useful technique for several applications. 
Ovulation control is useful in a timed breeding scenario, including breeding with frozen semen 
or dealing with limited stallion availability resulting from events such as competition schedules. 
Ovulation synchronization is also necessary and utilized extensively when synchronizing a donor 
mare and recipients for use in an embryo transfer program. Synchronization of ovulation in the 
mare can be more difficult than in other species because of prolonged estrous and diestrous 
periods (Ginther, 1992). In addition, some mares also are able to ovulate during diestrus (Claes et 
al., 2017), decreasing the efficacy of a protocol. Insemination of the mare is the most successful 
when conducted during a short period of time close to ovulation. The best chance of conception 
occurs when a mare is inseminated from 24 before up to 12 h post-ovulation (Sieme et al., 2003); 
however, clinical recommendations are generally to inseminate 48 h prior and up to 6 h post-
ovulation.  
The most widely accepted and used protocol for synchronization in the mare is 
administration of exogenous progesterone and estradiol (P+E; Mottershead, 2004, Loy et al., 
1981). Briefly, the 19-day protocol involves injections of 150 mg progesterone and 10 mg 
estradiol prepared in oil and administered daily for 10 days. A single injection of PGF2α is 
administered on day 10 of P+E treatment. Mares are administered an ovulatory agent on d 18 and 
inseminated on d 19. The 10-d regimen of exogenous hormone administration has a negative 
effect on circulating gonadotropins and suppresses follicular activity (McCue, 2014). 
Approximately 85% of mares will respond appropriately to this synchronization protocol. In 
addition to a possible failure to respond to synchronization, this protocol requires daily handling 
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of horses and daily administration of intramuscular drugs. These pharmacological agents can 
also cause injection site reactions, which may become infected and painful (McCue, 2014).  
Other synchronization protocols commonly used are a single injection of PGF2α, 
commonly referred to as short cycling a mare, or two PGF2α injections spaced 12 d apart. 
Administration of PGF2α may have negative side effects when administered to some horses, such 
as sweating, abdominal discomfort, and diarrhea (McCue, 2014).  Effectiveness of PGF2α 
treatment depends on stage of the estrous cycle at the time of administration and requires a 
functional CL. Luteolysis initiated by exogenous PGF2α administration will only be effective 
from approximately d 5 when the CL acquires functional receptors for PGF2α to d 14 of the 
estrous cycle, when endogenous PGF2α release will initiate luteolysis. In addition, variability 
exists in the return to estrus depending on follicle size/maturation level at the time of PGF2α 
administration (Loy et al., 1981).  
A final common synchronization protocol calls for the administration of P4 via an oral or 
injectable route to maintain elevated P4 concentrations for 14 d. Administration of PGF2α is 
concurrent with the final day of P4 treatment. In some mares, P4 alone isn’t able to suppress 
ovulation and they may ovulate during treatment (Hughes et al., 1972). On the other hand, a 
mare in late estrus may respond to P4 administration by holding a large, pre-ovulatory follicle for 
much longer than normal and when stimulated to ovulate, ovulate an aged oocyte that may lead 
to decreased embryo survival if the oocyte is fertilized (Carnevale, 2008). Long-term 
administration of P4 may also lengthen the interval to ovulation by long-term suppression of 
circulating LH (McCue, 2014). This protocol also requires daily handling and administration of 
drugs if the P4 is administered orally. Injectable forms of P4 limit the amount of handling to one 
or two injections; however, injection site reactions may be observed. In addition, success of 
15 
exogenous P4 administration to synchronize ovulation is only effective during certain times of 
the year when a normal cyclic activity has been established.  
 Transvaginal Ultrasound-Guided Follicular Ablation 
 Protocol 
Follicular ablation (FA) has been used recently as a synchronization tool in other species 
and has the advantages of reduced animal handling requirements, little to no use of exogenous 
hormones and no dependence of the animals’ estrous cycle stage (Bergfelt et al., 2007). While 
the specific equipment may vary, the procedure generally follows a standard protocol. For this 
procedure, a mare is restrained in stocks and sedated, generally with the addition of an 
antispasmodic agent, and the perineum is washed. Usually an analgesic such as lidocaine is 
applied to the vaginal wall before the introduction of the transducer. The ultrasound transducer is 
then inserted vaginally while the ovary is manually manipulated adjacent to the vaginal wall by 
rectal palpation. A needle is advanced through the transducer, and guided by the ultrasound 
image of the ovary, through the vaginal wall and into the ovary. Care is taken to pass through as 
much ovarian stroma as possible before puncture of the follicle, particularly in procedures where 
follicle rupture or total ablation is not the objective. Based on the aim of the procedure, follicular 
contents such as oocytes and follicular fluid may now be aspirated with the use of a vacuum 
pump or simple backpressure applied with a large syringe, or medications and/or oocytes may be 
placed into the penetrated follicle. There are many factors that can and do affect the success of 
the procedure. These can include equipment choices such as needle size, treatment differences 
such as hormone administration and aspiration frequency, and individual animal variation such 
as breed, stages of the estrous cycle and follicular size (Squires and Cook, 1996). 
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While rare, there are a few complications that have been noted with this procedure. 
Because a follicle, particularly a periovulatory follicle, has a highly vascularized follicular wall, 
small amounts of blood may be appreciated in collected follicular fluid. The presence of large 
amounts of blood could indicate more severe problems such as internal hemorrhaging 
(Vanderwall and Woods, 2002). Other complications that have been reported include ileus, 
peritonitis and colic (Carnevale, 2008). No significant effects on fertility in the mare have been 
found on subsequent inseminations following FA (Mari et al., 2005, Vanderwall et al., 2006).  
 Application of Follicular Ablation 
With the addition of FA as an assisted reproductive technique, the procedure has been 
used in a number of species both clinically and experimentally, to investigate a variety of 
objectives (Carnevale, 2008). In cattle, FA has been used to study gamete recovery and 
intrafollicular oocyte transfer in heifers (Bergfelt et al., 1998), follicular fluid hormone dynamics 
(Aller et al., 2013), as a technique for intrafollicular drug administration (Kot et al., 1995) and to 
study luteal function (Bisinotto et al., 2012). Additional studies in cattle have shown the use of 
FA before superovulation increased the number of ova/embryo output, albeit mostly 
nontransferable ova (Shaw and Good, 2000). The FA procedure also improved ovarian response 
as evidenced by increased production of oocytes and increased the number of embryos collected 
in early lactation (Amiridis et al., 2006). Ablation also has been reported to be as efficacious as 
P+E in synchronizing follicular wave emergence in cattle (Baracaldo et al., 2000), and it 
improved the superovulatory response in cattle as evidenced by a greater number of ova and 
embryos collected (Sendag et al., 2008, Lima et al., 2007). In pigs, FA has been utilized to study 
its effects on post-weaning anestrous intervals (Cox et al., 1987). Ablation has also been used in 
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estrous synchronization in wapiti (McCorkell et al., 2008) and to collect oocytes from 
superstimulated bison (Palomino et al., 2016). 
The FA procedure also has extensive application for clinical and experimental purposes 
in the horse. Research benefits include studying follicular dynamics (Ginther et al., 2009) and 
injection of pharmacological agents directly into follicles (Ginther et al., 2014). Unlike other 
species, horses respond poorly to superovulation protocols and are bound by the anatomical and 
physiological limitations of the ovulatory fossa, making the collection of multiple embryos at a 
single time point difficult. Equine oocytes and embryos also have poor maturation rates in vitro 
(Deleuze et al., 2009). These two reproductive hurdles have been targeted for study using the FA 
procedure in combination with other in vivo techniques such as intra-oviductal oocyte transfer 
and intra-follicular oocyte transfer to circumvent inadequacy of in vitro fertilization in horses 
(Deleuze et al., 2009, Carnevale et al., 2000, Hinrichs and DiGiorgio, 1991). Due to an extended 
period of seasonal anestrus, FA provides the opportunity to collect oocytes from mares that are 
not cycling and also while carrying a pregnancy (Purcell et al., 2007).  
Follicular ablation has been used in several species to initiate a new follicular wave and 
synchronize a cohort of animals. Ovulation synchronization facilitated by FA has been shown to 
be successful in cattle (Martinez et al., 2000, Bergfelt et al., 1994). Ablation has been more 
widely used in cattle to initiate a new follicular wave for superovulation treatment in an embryo 
collection program (Barcaldo et al., 2000, Bergfelt et al., 1997). The initial follicular wave in 
cattle is less variable, and when initiation of the first follicular wave is synchronized, the total 
group synchrony is tighter. Variability in synchronization protocols can potentially be attributed 
to stage of the estrous cycle and corresponding follicular development at the onset of drug 
administration.  
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In a previous report, use of FA was applied to synchronize a large group of mares on 
random days of the estrous cycle (Bergfelt et al., 2007). Following the ablation procedure, the 
FSH surge and deviation of the future dominant follicle were more synchronized, LH 
concentrations were greater before and after deviation, E2 concentrations were greater following 
deviation and follicles grew at a faster rate (Ginther et al., 2008, Cook 1995, Hinrichs et al., 
1991). Removal of the dominant follicle(s) is not only useful for synchronizing ovulation in 
mares but can also have potential application for delaying ovulation. By utilizing FA to remove 
the dominant follicle(s) destined to ovulate, the estrous cycle is “restarted” and time to ovulation 
could be longer than letting the dominant follicle continue to ovulation. 
 Use of Follicular Ablation in the Postpartum Mare 
In many disciplines, such as racing and showing, there are competitive advantages related 
to size and training level for foals born earlier in the year compared with their later counterparts, 
especially when sold at yearling sales or when raced or competed as 2 and 3 yr olds. Therefore, a 
need exists to have a mare conceive and foal as close to January 1 as possible. For a mare to 
maintain an early annual foaling interval, she must become pregnant again within weeks of 
parturition. Most mares have normal follicular development and ovulate during this initial 
postpartum interval, referred to as foal heat, by day 20 postpartum (Loy, 1980).  Timing of the 
first postpartum ovulation has a significant effect on pregnancy rates associated with that 
ovulation. If a mare ovulates before day 5-6 or 7-8 postpartum, there is a 0% and 32% chance of 
conception, respectively. If ovulation occurs 9-12 days postpartum, conception rates rise to 60%, 
and when ovulation occurs later than day 12, conception rates rise again to 75%, which is 
considered an acceptable rate and would be comparable with other normal ovulations (Zent, 
2006). The lower pregnancy rates associated with an early ovulation are due to a number of 
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factors including incomplete uterine involution, fluid sequestered in the uterine lumen, infection, 
inflammation and other traumatic events, such as cervical and uterine trauma, around foaling 
(Zent, 2006).  Mares have the best chance of conceiving on foal heat and maintaining a yearly 
foaling interval if the interval from foaling to ovulation is at least 12 days but less than 25 days. 
If the initial postpartum ovulation could be delayed, allowing for a greater chance of conception 
without the added time associated with electing to breed on the mare’s second natural cycle, 
foaling the subsequent year could take place within the appropriate time period. 
Several hormone administration protocols exist to lengthen the interval from parturition 
to ovulation in the mare. Exogenous oral or injectable P4 and P+E protocols, as previously 
described, have successfully lengthened this interval; however, administration of exogenous 
progesterone may close a mare’s cervix at a time period when an open cervix is necessary for 
uterine clearance of debris from the foaling process, potentially creating uterine infections and 
other issues that would negatively impact future fertility (Zent, 2006). 
Follicular ablation has been performed successfully in several species such as cattle 
(Martinez et al 2000, Barcaldo et al., 2000, Bergfelt et al., 1994) and horses (Carnevale, 2008, 
Bergfelt et al., 2007). This procedure has been used to synchronize ovulation, initiate new 
follicular waves for superovulation treatment, and for oocyte collection and transfer. Further 
investigation into the comparison of FA to conventional P+E protocols for ovulation 
synchronization is warranted. Studies have not yet been conducted to determine if follicular 
ablation could be useful in delaying the postpartum interval to ovulation in the mare.  
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Chapter 2 - Application of the follicular ablation technique in mares 
 Abstract 
Two experiments were conducted to determine the practicality of utilizing transrectal 
ultrasound-guided follicular ablation in a commercial setting. The objective of the initial 
experiment was to investigate the efficacy of follicular ablation as a technique for ovulation 
synchronization when compared with a standard progesterone and estrogen (P+E) protocol. 
Twenty non-pregnant mares were assigned to an ovarian follicular ablation (FA, n = 10) or P+E 
treatment (n = 10). Briefly, FA mares were subjected to follicular ablation to remove all follicles 
> 10 mm on d 1 and administered prostaglandin F2α (PGF2α) twice on d 5. Mares were 
administered 2,500 IU human chorionic gonadotropin (hCG) on d 11 and evaluated via 
ultrasound twice daily until ovulation was detected. Mares in the P+E treatment were scanned at 
initiation of the protocol and received P+E IM once daily for 10 d. On d 10, mares received 
PGF2α and ultrasound monitoring began on d 15. On d 18, mares were administered hCG and 
evaluated twice daily until ovulation was detected. Interval from initiation of treatment to 
ovulation (10.4 vs 19.1 d) and the interval from hCG administration to ovulation (28.8 vs. 55.5 
h) was shorter (P<0.01) in the FA mares versus the P+E mares, respectively. Ablation may be an 
acceptable non-steroidal alternative to the conventional P+E protocol and can shorten the interval 
from treatment to ovulation.  
The objective of the second experiment was to determine if ablation could prolong the 
interval from parturition (d 0) to the first postpartum ovulation. Eighteen postpartum mares were 
assigned to a FA treatment (n = 10) or untreated control (CON; n = 8). On d 6, FA mares were 
subjected to follicular ablation to remove all follicles > 10 mm. Mares were administered PGF2α 
twice on d 11 and monitored via ultrasound once daily until a follicle ≥ 35 mm was detected, at 
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which time mares were treated with 2,500 IU of hCG. After hCG, mares were monitored twice 
daily until ovulation was detected. The CON mares were evaluated using ultrasound beginning 
on d 4, continuing every other day until a follicle ≥ 30 mm was detected at which time scanning 
frequency increased to once daily. When a follicle ≥ 35 mm was identified, mares were 
administered hCG and monitored twice daily until ovulation was detected. Interval from foaling 
to ovulation was longer (P<0.01) in the FA mares (15.9 d) compared with CON mares (10.0 d). 
Increasing the interval from foaling to ovulation is known to increase conception rates; therefore, 
application of this procedure could be utilized to optimize the timing of breeding, thereby 
improving overall pregnancy rates. Results from these experiments support the commercial 
application of follicular ablation in synchronization programs and delaying ovulation in the early 
postpartum mare. 
Keywords: mare, follicle ablation, postpartum ovulation, synchronization 
 Introduction 
Transvaginal ultrasound-guided follicular ablation (FA) is a relatively low risk procedure 
that has been studied in many species and has been used for a variety of objectives. Initially 
developed as a research tool, FA was first studied as a method to collect embryos from cattle 
(Pieterse et al., 1988). In the horse, it has been used for a number of clinical and experimental 
purposes. Research applications include studying follicular dynamics (Ginther et al., 2009a,b) 
and intra-follicular administration of pharmacological agents (Ginther et al., 2014), and oocyte 
collection and intra-follicular transfer (Carnevale, 2004). Compared with other species, horses 
respond poorly to superovulation protocols and are bound by physiological limitations of the 
ovulatory fossa, making collection of multiple embryos at a single time point difficult (Ginther, 
1992). Equine oocytes and embryos also have poor maturation rates in vitro (Deleuze et al., 
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2009). Using the FA procedure in combination with other in vivo techniques, such as intra-
oviductal oocyte transfer and intra-follicular oocyte transfer, researchers have attempted to 
overcome obstacles associated with in vitro oocyte fertilization in mares (Hinrichs and 
DiGiorgio, 1991, Carnevale et al., 2000, Deleuze et al., 2009). Because mares are also seasonally 
polyestrous, the FA technique offers the ability to collect oocytes from mares during anestrus 
(Purcell et al., 2006). Using the FA procedure, collection of oocytes from mares carrying a 
pregnancy also has been reported (Purcell et al., 2006). Collected oocytes may be frozen, 
fertilized in vitro, or utilized for intra-follicular oocyte transfer.  
Traditional synchronization protocols in mares and other species involve the repeated 
administration of exogenous hormones. The most widely accepted protocol for synchronization 
of ovulation in the mare is administration of exogenous progesterone and estradiol (P+E; 
Mottershead, 2004). Briefly, the 19-d protocol involves injections of 150 mg progesterone and 
10 mg estradiol prepared in oil and administered daily for 10 d. A single injection of PGF2α is 
administered on day 10 of P+E treatment. Mares are administered an ovulatory agent on d 18 and 
inseminated on d 19. The FA procedure offers an alternative method for initiating a new 
follicular wave (Bergfelt et al., 1997), and also removes the necessity of exogenous steroid 
administration and decreases the labor associated with daily handling. Following ablation in the 
mare, the FSH surge and deviation of the dominant follicle were more synchronized, LH 
concentrations were greater before and after deviation, E2 concentrations were greater following 
deviation and follicles grew at a faster rate (Hinrichs et al., 1991, Cook 1995 Ginther et al., 
2008). A previous study investigated the use of FA to synchronize a large group of mares and 
acceptable synchronization rates were achieved (Bergfelt et al., 2007). The objective of 
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experiment 1 was to determine if FA achieved similar or enhanced ovulation synchrony 
compared with the current P+E treatment. 
In many disciplines, such as racing and competitive showing, earlier born foals have the 
advantage of both size and level of training over their counterparts born later in the year. For 
foals to be born early in the year, mares must conceive by early February to foal as close as 
possible to January 1 of the following year. For a mare to maintain a yearly foaling interval, on 
average, she must become pregnant again within 25 d of parturition. Most mares have normal 
follicular development and ovulate by d 20 postpartum (Loy, 1980).  Timing of first postpartum 
ovulation has a significant effect on fertility associated with that ovulation. If ovulation occurs 
beyond d 12 postpartum, pregnancy rates increase to more acceptable values (Loy, 1980). The 
poorer pregnancy rates associated with earlier ovulation result from a number of factors 
including incomplete uterine involution, fluid sequestered in the uterine lumen, infection, 
inflammation and other traumatic events, such as cervical trauma and tearing, around the time of 
foaling (Vanderplassche et al., 1983, Zent, 2006).   
In most cases, by extending the interval from parturition to ovulation by only a few days, 
normal pregnancy rates can be achieved, eliminating the need to postpone breeding until the 
second postpartum estrous cycle. Several hormone protocols exist that can lengthen the interval 
from parturition to ovulation in the mare. Exogenous P4 and P+E protocols successfully lengthen 
this interval; however, administration of exogenous P4, particularly to mares with a history of 
poor uterine clearance, may increase the tone of a mare’s cervix and decrease uterine motility, 
negatively impacting uterine clearance (McKinnon et al., 1988), and poorer immune function, 
reducing the ability of the mare to clear accumulated bacteria (Leblanc et al., 2011). In addition, 
some mares may ovulate despite postpartum exogenous P4 administration (Loy et al., 1975). 
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Follicular ablation has been performed successfully in several species, including cattle 
(Bergfelt et al., 1994, Barcaldo et al., 2000, Martinez et al., 2000) and horses (Bergfelt et al., 
2007, Carnevale, 2008). To date, no studies have been conducted to determine if follicular 
ablation could delay the timing of ovulation in the mare. The objective of experiment 2 was to 
determine if follicular ablation could delay the initial postpartum ovulation thereby increasing 
the chances of establishing an earlier successful pregnancy and while maintaining a yearly 
foaling interval. 
 Materials and Methods 
 Experiment 1 
 Animals and Treatments 
This study was reviewed and approved by the Kansas State University Animal Care and 
Use Committee before study initiation. Twenty non-pregnant, stock-type mares, ranging from 8 
to 20 yr old, were used for this experiment. All mares were group-housed in small lots (1 to 3 
acres) with minimal grass cover and received a concentrate and forage diet formulated to meet or 
exceed NRC requirements (NRC, 2007). Mares had ad libitum access to water and a trace 
mineral supplement. Before initiation of the study, mares were monitored via transrectal 
ultrasound (Medison Sonovet 600; Samsung Medison, Ridgefield Park, NJ) equipped with a 5 
MHz linear transducer until ovulation was detected. Ovulation was characterized by the 
disappearance of the dominant follicle and subsequent corpora lutea formation. Pre-treatment 
observation continued until ovulation was observed in all mares, confirming mares were cycling 
normally. Treatment protocols were initiated on the same day for all mares.  
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Following ovulation, mares were assigned randomly to the follicular ablation treatment 
(FA; n = 10) or to receive progesterone and estradiol treatment (P+E; n = 10). Mares in the FA 
treatment were scanned on d 1 of treatment and all follicles > 10 mm were targeted for removal 
by follicular ablation. On d 5 (4 d post-FA) each mare received two injections of PGF2α (10 
mg/dose, IM, Lutalyse®; Zoetis, Florham Park, New Jersey) 12 h apart. Six days after PGF2α 
administration (d 11 post-FA), mares received hCG (2,500 IU, IV, Chorulon®; Intervet Inc., 
Millsboro, DE) and were monitored via ultrasound twice daily at 0800 h and 2000 h until 
ovulation was detected. The FA protocol (Fig. 2.1) used in this experiment was reported 
previously (Bergfelt et al., 2007). Mares completed the experiment once ovulation was detected. 
 
Ovaries in the P+E mares were scanned via ultrasound on the day P+E was initiated (d 1). 
Following a standard 19 d P+E protocol (Fig. 2.2), 150 mg of progesterone (P4) and 10 mg 
estradiol 17-β (E2) were administered IM at 0800 h each day for 10 d (Mottershead, 2004, Loy et 
al., 1981). On d 10, mares also received PGF2α (10 mg/dose, IM, Lutalyse®; Zoetis, Florham 
Park, New Jersey) concurrent with the final P+E dose. Eight days after the initial prostaglandin 
injection (d 18), mares were administered hCG (2,500 IU, IV, Chorulon®; Intervet Inc., 
Figure 2.1 Time line for ovulation synchronization procedural design for the FA treatment 
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Millsboro, DE) and monitored via ultrasound twice daily at 0800 h and 2000 h until ovulation 
was detected. Mares completed the study once ovulation was detected.  
 
 
 Ablation Procedure 
For the ablation procedure, mares were restrained in stocks and sedated using detomidine 
hydrochloride (0.01 mg/kg, IV, Dormosedan, Zoetis, Florham Park, New Jersey). In addition, N-
butylscopolammonium bromide (0.3 mg/kg, IV, Buscopan, Boehringer Ingelheim, St. Joseph, 
MO) was administered concurrently in order to relax the rectum before manipulation of the 
ovary. The tail of each mare was wrapped and pulled to the side and the perineum was washed in 
an aseptic manner. The FA procedure was performed using an ultrasound scanner (Aloka SSD-
500; Diagnostic Medical Devices, Tokyo, Japan) using a 5.0 MHz convex-array transducer 
equipped with a 17-gauge 53.3 cm needle. Before the transducer was introduced into the vagina, 
a 2% topical Lidocaine gel (Xylocaine 2% Jelly; Akorn Pharmaceuticals, Lake Forest, IL) was 
manually applied where the needle would puncture the vaginal wall in order to numb the area 
and reduce potential discomfort. Once the transducer was inserted into the vagina, the ovary 
selected for targeting was manipulated per rectum towards the transducer. The needle was 
advanced through the vaginal wall into the selected follicles (> 10 mm in diameter) and the 
Figure 2.2 Time line for ovulation synchronization procedural design for the P+E treatment 
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follicular contents were evacuated by applying back pressure with a sterile syringe connected to 
the tubing attached to the transducer needle.  
 Statistical Analyses 
Data were analyzed using the GLM procedure in SAS (version 9.1, Cary, NC). 
Differences in treatments were evaluated using ANOVA. The model included treatment to 
determine the following outcomes: stage of the estrous cycle at treatment onset, interval from 
onset of treatment to ovulation, days from hCG administration to ovulation, hours from hCG 
administration to ovulation, days from initial PGF2α administration to ovulation, diameter of 
follicle ovulated, incidence of double ovulation and the diameter of the follicle at hCG 
administration. Binomial data defined as the percentage of mares synchronized in each group at 
d 2 and 4 was also calculated and analyzed using Chi-square.  Data are presented as least squares 
means ± SEM. Significance was determined at P<0.05. 
 Experiment 2 
 Animals and Treatments 
This study was reviewed and approved by the Kansas State University Institution Animal 
Care and Use Committee before study initiation. For Experiment 2, 18 postpartum stock-type 
mares, ranging from 4 to 16 yr of age, were enrolled. All mares were group-housed in small lots 
with grass cover and received a concentrate and forage diet formulated to meet or exceed NRC 
requirements (NRC, 2007) for mares in early lactation. Mares had ad libitum access to water and 
a trace mineral supplement. Before the expected foaling date, mares were assigned randomly 
assigned to either of two treatments: follicular ablation (FA, n = 10) or an untreated control 
(CON, n = 8). All mares began the experiment at parturition (d 0). 
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Ovaries of FA mares were evaluated via ultrasound beginning on d 6. All follicles > 10 
mm were removed on d 6 using the ablation procedure as previously described. On d 11 (5 d 
post-FA), each mare received PGF2α (10 mg/dose, IM, Lutalyse®; Zoetis, Florham Park, New 
Jersey) at 0800 h and 2000 h. Beginning on d 12, mares were monitored via ultrasound every 
other day until a follicle ≥ 30 mm was first observed. Once a 30 mm follicle was detected, 
scanning frequency increased to once daily day until a follicle ≥ 35 mm was measured, at which 
time mares received hCG (2,500 IU, IV, Chorulon®; Intervet Inc, Millsboro, DE). After 
treatment with hCG, mares were monitored via ultrasound twice daily until ovulation was 
detected (Fig. 2.3).   
 
Control mares were scanned via ultrasound beginning on d 6. Follicular development was 
monitored every other day until a follicle ≥ 30 mm was detected. Once a 30 mm follicle was 
detected, scanning frequency increased to once daily until a follicle ≥ 35 mm was measured, at 
which time mares received hCG (2,500 IU, IV, Chorulon®; Intervet Inc, Millsboro, DE). 
Figure 2.3 Procedural time line for delaying ovulation post-foaling using follicular ablation (FA) 
treatment 
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Following hCG, mares were monitored via ultrasound twice daily until ovulation was detected 
(Fig. 2.4).  All mares completed the experiment on d 5 post-ovulation. 
 
 Blood Collection and Analyses 
Daily 10-mL blood samples were collected from all mares via jugular venipuncture at 
0800 h into evacuated tubes beginning on d 6 and continued until d 5 post-ovulation. Blood 
samples were allowed to clot for 30 min at room temperature and then centrifuged at 2,500 x g 
for 20 min. Serum aliquots were stored at -20°C for future analysis. Serum samples were 
analyzed in one assay for progesterone (DSL-3900 ACTIVE® Progesterone Coated-Tube RIA 
kit, Diagnostic Systems Laboratories, Inc., Webster, TX). Assay sensitivity was 7.21 pg/ml and 
the intra-assay CV was 6.2%. This assay was previously validated in the equine and conducted 
according to the manufacturer protocol (Schmidt, 2010).  
Figure 2.4 Procedural time line of mares left allowed to cycle normally post-foaling as 
untreated controls (CON) 
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 Statistical Analyses 
Data were analyzed using the GLM procedure in SAS (version 9.1, Cary, NC). 
Differences in treatments were evaluated by using ANOVA. The model included treatment to 
determine the following outcomes: the interval from start of treatment to ovulation, days from 
hCG administration to ovulation, hours from hCG administration to ovulation, days from initial 
PGF2α administration to ovulation, diameter of follicle ovulated, incidence of double ovulation 
and the diameter of the follicle at hCG administration. A cutoff point of > 1 ng/mL was used to 
determine luteal function. Concentrations of P4 were not different for each mare from d 6 to 
ovulation; therefore, P4 samples were pooled and analyzed as a single mean between treatments. 
Data are presented as least squared means ± SEM. Significance was determined at P<0.05. 
 Results 
 Experiment 1  
Three FA mares and one P+E mare ovulated before hCG administration. One FA mare 
did not respond to hCG administration and did not ovulate before the end of the experiment. 
Data for these 5 mares were excluded from the interval from hCG administration to ovulation 
analysis. Interval from the initiation of treatment to ovulation, interval from hCG administration 
to ovulation, and interval from PGF2α administration to ovulation were shorter (P<0.01) in FA 
mares compared with P+E mares. No treatment differences (P>0.05) were detected for incidence 
of double ovulation, diameter of the follicle at the time of hCG administration, or diameter of the 
follicle at ovulation. Rate of synchronization was calculated both including and excluding the 3 
FA mares and 1 P+E mare that ovulated before hCG administration. Excluding those 4 mares, 
synchronization rates at 2 and 4 d post-ablation did not differ (P>0.05). Although numerically 
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greater in the P+E treatment, no difference in synchronization rates was detected when these 4 
mares were included (Fig. 2.5, Table 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Distribution of the number of mares ovulating (OV) in response to treatment. 
Ovulation was synchronized by daily administration of progesterone and estradiol (P+E; n = 10) 
beginning on d 1 for 10 d with prostaglandin F2α (PGF2α) administered on d 10, and human 
chorionic gonadotropin (hCG) administered d 18 or all ovarian follicles > 10 mm were ablated 
transvaginally (FA; n = 9) on d 1 followed by administering PGF2α twice 12 h apart on d 5 and 
hCG administered on d 11.  
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Table 2.1 Reproductive traits of mares in which ovulation was synchronized by either follicular 
ablation (FA) or a 10-d protocol of daily progesterone and estradiol (P+E) administration and 
follicles were monitored by transrectal ultrasonography until ovulation (OV) occurred. 
 Treatment
c 
Trait FAa P+Eb 
Treatment to OV (d)f 10.4 ± 0.4d 19.1 ±  0.4e 
Interval from hCG to OV (h)f 28.8 ± 6.3d 55.5 ± 5.0e 
Interval from PGF2α to OV (h)
f 6.5 ± 0.4d 10.1 ± 0.3e 
Follicle size at hCG (mm)f 34.6 ± 2.2 32.9 ± 1.7 
Follicle size at OV (mm)g 36.9 ± 1.7 33.9 ± 1.6 
No. of mares synchronized within 2 d of first OV 6/7 7/9 
No. of mares synchronized within 4 d of first OV 6/7 8/9 
No. of mares synchronized within 2 d of first OV 6/10 7/10 
No. of mares synchronized within 4 d of first OV 6/10 8/10 
No. of mares that double ovulatedg 2 2 
aAblation of follicles >10 mm followed by prostaglandin F2α (PGF2α) administration twice 12 h 
apart on d 5 and human chorionic gonadotropin (hCG) on d 11. 
bProgesterone (150 mg) and estradiol (10 mg) administered once daily beginning on d 1 for 10 d 
followed by PGF2α on d 10 and hCG on d 18. 
cValues are listed as LSMeans ± SEM. 
d,eValues within a row lacking a common superscript differ (P<0.01). 
fn=7 for FA mares, n=9 for P+E mares. 
gn=10 for FA mares, n=10 for P+E mares. 
 
 Experiment 2  
 Mare Reproductive Traits 
Interval from foaling to ovulation was greater (P<0.01) in the FA treatment compared 
with controls (Figure 2.6). No treated differences (P>0.05) were observed for the interval from 
hCG administration to ovulation, incidence of double ovulation, or diameter of the largest 
follicle at the time of ovulation (Table 2.2).  
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Table 2.2 Reproductive traits of early postpartum mares whose follicles >10 mm were targeted 
for removal by follicular ablation on d 6 post-foaling (FA) or allowed to cycle normally after 
foaling (CON) and monitored by transrectal ultrasonography until ovulation (OV) occurred. 
 
Treatmentc 
Trait FAa CONb 
Days from foaling to OV 15.8 ± 0.9d 10.0 ±  1.1e 
Hours from hCG to OV 60.0 ± 6.5 48.0 ± 7.9 
No. of mares that double ovulated 1 1 
Follicle diameter at OV (mm) 43.7 ± 2.3 43.0 ± 2.8 
Progesterone d 6 until OV (ng/mL) 1.1 ± 0.6d 0.2 ± 0.0e 
aOn d 6 postpartum, all follicles > 10 mm were targeted for removal via follicular ablation 
followed by (prostaglandin F2α) PGF2α administration on d 11 and human chorionic 
gonadotropin (hCG) administration when a follicle ≥ 35 mm. 
bAdministration of hCG when a follicle ≥ 35 mm. 
cValues are listed as LSMeans ± SEM; FA n=10, CON n=8. 
d,eValues within a row lacking a common superscript differ (P<0.01). 
Figure 2.6 Distribution of the number of mares ovulating (OV) and days to ovulation after 
foaling (d 0) for mares whose follicles >10 mm were ablated on d 6 (FA, n=10), 
administered prostaglandin F2α (PGF2α) on d 11, and given human chorionic gonadotropin 
(hCG) once a follicle ≥ 35mm was detected. Control mares were allowed to cycle normally 
from foaling (CON, n=8) and given hCG when a follicle ≥ 35 mm was detected. 
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 Progesterone Concentrations 
Average P4 concentrations from d 6 until OV were not different within each mare; 
therefore, P4 was pooled and analyzed as a single data point between treatments. Concentrations 
of P4 were greater (P<0.01) in FA mares when compared with CON mares (Table 2.2). Two 
mares in the FA group had elevated serum progesterone concentrations consistent with luteal 
tissue production. When data were removed for these two mares, no difference in average P4 
concentrations was observed (P>0.05). No correlation was detected between average, baseline 
and median P4 concentrations and size of the follicle at ovulation (P>0.05). 
 Discussion 
Current ovulation synchronization protocols dictate daily handling of mares and 
administration of exogenous hormones. The FA procedure has been utilized in other species to 
synchronize ovulation and offers the advantage of decreased handling and elimination of 
exogenous steroid hormone administration. Experiment 1 was conducted to determine if FA 
achieved comparable synchrony compared with P+E. Within a 4-d window from the initial 
observed ovulation, the overall rate of synchronization was 86% and 88% for the FA and P+E 
group, respectively. These results were consistent with previous findings for rates of synchrony 
within both treatments (Bergfelt et al., 2007). When data were included for the 3 FA mares and 1 
P+E mare that ovulated before hCG administration, synchronization rates fell to 60% in FA 
mares, which was less than what was achieved with the P+E treatment; however, the difference 
was not significant. Reported synchronization rates for a 4-d window when using P+E range 
from 72% to 94% (Loy et al., 1981, Taylor et al., 1982) and this is comparable with the rate of 
synchrony achieved in this experiment. Acceptable and comparable synchrony between the two 
treatments was achieved when early-ovulating mares were excluded. When all mares were 
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included in the synchronization analysis, a greater variability of success was observed in the FA 
treatment. While ovulation synchronization was the objective of Experiment 1, it is important to 
note that the FA procedure shortened the interval from treatment initiation to ovulation when 
compared to P+E. Shortening the treatment to ovulation interval may make this procedure more 
attractive and warrants further investigation into the effects of narrowing the post-treatment time 
line. 
Although stage of the estrous cycle at the beginning of treatment was recorded, it was not 
a significant factor in predicting whether or not synchronization would be successful and/or 
premature ovulations would occur. Compared with spontaneous follicular growth rates, it has 
been reported that follicles grow at a faster rate following an ablation procedure (Hinrichs et al., 
1991, Cook 1995, Ginther et al., 2008) and this could have contributed to early ovulations 
observed before hCG administration in this experiment. Another contributing factor to this rapid 
ovulation could have been the presence of large follicles during the ablation procedure. When 
large follicles are targeted for ablation they can have confounding effects on the success of the 
procedure. These large follicles can regenerate follicular fluid to refill their antrum and regain or 
maintain dominance and go on to ovulate approximately 5% of the time (Bergfelt et al., 1994) or 
they can potentially develop luteal tissue and begin producing progesterone (Bergfelt and 
Adams, 2000). Luteinization of these large, and sometimes variable-sized follicles illustrates the 
necessity of PGF2α administration following ablation, but perhaps a different administration 
interval than the one used in this study would be more beneficial to ensuring luteolysis. 
Generally, a 5-d interval from ovulation is required for prostaglandin receptors located within the 
plasma membrane of luteal cells to mature and respond to PGF2α administration (Senger, 2005). 
In the FA synchronization protocol, only 4 and 4.5 days had passed before administration of 
36 
PGF2α. This timing was utilized in the current experiment based on previous reports of the use of 
this administration interval (Bergfelt et al., 2007). Lengthening this interval to PGF2 
administration could enhance the luteolytic response of the luteal cells and guarantee more 
successful luteolysis. Interval from initiation of treatment to ovulation in both the FA and P+E 
mares was shorter than previously reported (Bergfelt et al., 2007); however, in this study, the 
P+E protocol was adjusted to administer hCG on d 18 versus d 20 to follow closely more recent 
reports of this synchronization protocol (Loy, 1981, Mottershead, 2011), which may explain the 
shorter interval in the P+E treatment in this experiment.  
Size of the follicle at the time of hCG administration is a critical component to the 
success of the ovulation-inducing agent. The administration of hCG is recommended when a 
follicle is > 35 mm in size, which will generally induce ovulation by 24 to 48 h post-
administration (McCue, 2009). Interval from hCG to ovulation was within the predicted and 
acceptable window for the FA mares and was slightly longer than expected in the P+E mares. 
This longer interval may have been the result of the larger follicle size at the time of hCG 
administration in the FA treatment. Although close, neither group averaged a 35-mm follicle 
before administration of hCG. Set protocols for both treatments were followed to more closely 
follow current protocol directions. Administration of P+E has been shown to have a negative 
influence on circulating gonadotropin concentrations in mares (Evans et al., 1982). Although not 
measured in this study, decreased FSH or LH concentrations could have contributed to the 
slower follicular growth and longer interval from hCG administration to ovulation. To enhance 
the success of this protocol, more intensive monitoring may be employed to postpone hCG 
administration until the targeted follicle size of 35 mm has been reached.  
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Ovulation before hCG administration was observed in several FA mares and was 
potentially the result of incomplete removal of the follicle, which refilled and ovulated or 
perhaps became luteinized. Measurement of circulating progesterone concentrations would 
provide a more complete picture on whether the evacuated follicle(s) developed functional luteal 
tissue. In addition, measurements of all follicles that were ablated and ultrasound scanning of the 
mares in the days following the ablation procedure could provide useful data. Correlation data 
between size of ablated follicles and the predicted success of the procedure and the likelihood of 
a follicle to refill and ovulate or develop luteal tissue and begin producing progesterone would be 
beneficial. Although difficult on a large scale or in a commercial setting, more frequent 
ultrasound monitoring around the ablation procedure could provide useful insight into follicular 
dynamics following FA, particularly when used as a synchronization technique.  
Experiment 2 assessed the practicality of using the FA procedure in mares to extend the 
postpartum interval to the initial ovulation. Maintaining a yearly foaling interval by foaling as 
early in the year as possible is advantageous in many areas of equine production. Breeding on the 
initial cycle post-foaling presents the challenge of decreased fertility associated with ovulations 
that occur too soon after parturition. This decreased fertility is partly a function of incomplete 
uterine involution, fluid sequestered in the uterine lumen, infection, inflammation, and other 
events, such as cervical and uterine trauma, at foaling (Zent, 2006). On average, with 
consideration to gestation length, a mare should ovulate and conceive within 25 days post-
foaling to consistently produce a foal early in the next year. If ovulation occurs later than d 12 
postpartum conception rates rise to 75%, which is considered an acceptable rate and would be 
comparable with ovulations during a conventional estrous cycle (Zent, 2006). Even when a mare 
may not naturally ovulate before d 12, lengthening the postpartum interval to ovulation would be 
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useful when a mare is going to be inseminated with shipped semen or required an ovulation-
inducing agent to time breeding. Increasing the interval from foaling to ovulation also may be 
useful when a mare experiences mild dystocia during parturition. A few additional days before 
breeding would be beneficial to cervical and/or uterine repair and involution. To accomplish this 
goal of breeding between d 12 and 25, it is necessary to delay the expected first post-foaling 
ovulation period by 10 to 14 d (Loy et al., 1980). One method commonly used is administration 
of PGF2α 5 d after the initial ovulation is observed post-foaling, commonly referred to as short 
cycling. Short cycling can decrease the interval from the first to second ovulation by 
approximately 9 to 10 d; however, ovulation must first be detected to appropriately time PGF2α 
administration. In experiment 2, the aim was to determine if FA could be used to delay the 
postpartum interval to ovulation. On average, CON mares ovulated by d 10 postpartum. As 
discussed previously, breeding on this ovulation could have resulted in below average 
conception rates. The postpartum interval from foaling to ovulation in the FA treatment was 
increased to almost 16 d, which indicates pregnancy rates may have been improved over CON 
mares while falling within the necessary window to maintain a yearly foaling interval.  
Interval from hCG administration to ovulation in both treatments was highly variable and 
longer than anticipated. Considering hCG was administered to all mares at the target follicle 
diameter of 35 mm, and the size of the follicle at ovulation was similar between treatments, a 
more consistent response was expected. Although not significant, the interval from hCG to 
ovulation was longer in FA mares. Circulating P4 concentrations were analyzed from d 6 post-
foaling until ovulation to determine if any ablated follicles luteinized. Two mares in the FA 
group developed anovulatory hemorrhagic follicles (AHF) that produced progesterone following 
the ablation of large follicles. Both of these mares had follicles > 40 mm in size when the FA 
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procedure was performed. Complications with ablation or aspiration of large follicles that either 
refill and grow to ovulate or luteinize have been reported (Bergfelt and Adams, 2000). 
Administration of PGF2α on d 5 post-FA regressed the AHF in one mare but not the other.  
 Conclusions 
 In conclusion, the FA procedure synchronized mares with a similar success rate 
compared with P+E. In addition, and possibly more important, FA shortened the interval from 
treatment initiation to ovulation compared with the P+E protocol. The stage of the estrous cycle 
at treatment initiation and the uncertainty of the fate of targeted large follicles could create 
variability in the success of treatment and synchrony. Additional management-related benefits of 
FA include decreased labor associated with daily handling for many days and eliminating 
exogenous hormone treatment. The FA procedure is a viable alternative for synchronizing 
ovulation; however, limitations of its use can be appreciated as the level of training and 
specialized equipment needed may make this procedure unavailable to individual mare owners, 
smaller veterinary clinics or clinics lacking theriogenologists trained in this procedure.  
The FA procedure also successfully lengthened the interval from foaling to ovulation 
compared with untreated controls, and attained ovulation in the necessary window to both 
optimize conception rates and allow for a yearly foaling interval. Further research is necessary to 
determine if delaying ovulation, and thereby optimizing the conditions surrounding conception 
following FA, correlates with higher conception rates. Additional investigation into the effects of 
both lengthening and shortening the treatment interval to ovulation utilizing FA is warranted. 
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Chapter 3 - Review of Current Literature for Experiment 3 
 Introduction 
Horses are monogastric herbivores that are naturally designed to consume forage that is 
high in fiber and low in digestible energy. Domestication, in some cases, has altered the natural 
feeding tendencies of horses through the inclusion of meal feeding and the addition of 
concentrate rations. Horses, in general, are unable to tolerate high amounts of carbohydrates 
given at one time, which are fairly common in conventional concentrate rations. They are able to 
tolerate, however, large amounts of fat in their diet, which provides a caloric dense ration 
without the associated problems of feeding a high energy ration consisting of carbohydrates 
(Lewis, 2005, Bush et al., 2001). A horse can safely tolerate up to 20% of its diet as fat (Lewis, 
2005) and current fat-added feeds contain between 6 and 12% fat to supply a caloric dense ration 
without large amounts of carbohydrates. Because of this level of tolerance and the need for 
additional calories as a result of the performance activities of some horses, inclusion of fat in a 
horse's diet has become a common industry practice. Increased fat allows for greater dietary 
energy without negatively impacting the glycemic index as do traditional increases in cereal 
grains alone (Bush et al., 2001).  
Following the determination that horses are tolerant of fat-added diets, research was 
conducted to evaluate the effects of fat inclusion in the rations on many different classifications 
of horses (Hiney and Potter, 1996, Davison et al., 1991, Scott et al., 1989). In performance 
horses or horses in heavy work, positive benefits, such as decreased energy requirements and 
more efficient dietary energy usage and increased performance and recovery have been observed 
with the inclusion of additional fat in the diet (Hiney and Potter, 1996). Increasing fat in the diet 
supplies a safer alternative for providing a more energy-rich ration to horses with a heavy 
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workload (Hambleton et al., 1980). Harkins et al. (1992) found that skeletal muscle glycogen 
stores and resting glucose levels were increased, and race times were improved when racehorses 
were fed a high fat diet. In addition to performance-related benefits for the working horse, 
research has shown a variety of systems in a number of species will respond in a positive manner 
to dietary fat supplementation, including reproduction. The following review will discuss the 
types and sources of fat supplementation and its effects on reproduction and bone metabolism, 
including benefits to the horse and potential areas where further investigation is needed. 
 Fatty Acid Metabolism and Sources 
Earlier studies typically supplemented fat in the form of plant and vegetable oils without 
regard to the actual makeup of the fat being provided. Historically, the benefits of fat 
supplementation were generally attributed to the increased caloric content. Research also 
indicated however, a possible impact of certain fatty acids (FAs), in addition to the caloric value 
of a higher fat ration. More recently the focus has shifted to the specific type of fat, in the form 
of polyunsaturated fatty acids (PUFAs) and their relationship to growth, reproduction and 
performance.  
These FAs are characterized as a long hydrocarbon chain with a terminal carboxylic 
group in the alpha position and a methyl group at the omega position. The further definition of a 
FA is influenced by the position and number of the carbon to hydrogen (C-H) bond along the 
hydrocarbon chain. When the hydrocarbon chain is comprised of the maximum number of C-H 
bonds with no double bonds present, the fatty acid is categorized as a saturated fatty acid. The 
FAs that lack the maximum number of C-H bonds and contain double bonds are considered to be 
unsaturated FAs. Furthermore, if the hydrocarbon chain has more than one unsaturated, or 
double bond, it is characterized as a PUFA.  
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A PUFA can be further characterized as either an omega-3 (n-3), omega-6 (n-6) or 
omega-9 (n-9) FA depending on the position of the unsaturated bond located nearest the omega 
end of the hydrocarbon chain. When the unsaturated bond is located between the third and fourth 
carbons from the omega end, the FA is classified as an n-3 FA. When the unsaturated bond is 
located between the sixth and seventh and ninth and tenth carbons, the FA is classified as an n-6 
and n-9, respectively. Although many FAs are necessary for bodily processes, only alpha-
linolenic acid (ALA, C18:3) and linoleic acid (LA, C18:2) are considered essential because they 
cannot be synthesized by mammals due to the inability of mammalian desaturase enzymes to 
cleave beyond the ninth carbon from the alpha end of the hydrocarbon chain (Gurr et al., 2002). 
Essential fatty acids are an integral component of phospholipids and cell membranes (Kinsella, 
1991) and are critical for many body processes including growth, reproduction and vision and 
brain development (Gurr et al., 2002). These essential fatty acids can impact growth and 
reproduction due to their ability to influence steroidogenesis and some transcription factors 
controlling gene expression (Wathes et al., 2007). Prostaglandins, leukotrienes, thromboxanes, 
lipoxins, and resolvins are also metabolites formed from enzymatic conversion of fatty acids that 
can differentially influence a wide array of bodily functions (Das, 2006). 
Metabolism of the n-3 and n-6 FAs occurs in the liver where they undergo alternate 
desaturation and elongation reactions (Fig. 3.1) Each of these respective pathways utilize the 
same desaturase and elongase enzymes, which leads to competition between the pathways for 
intermediaries and subsequent production. The first enzyme to act upon the fatty acids is Δ-6 
desaturase, which converts LA to gamma-linolenic acid (GLA) and ALA to steroidonic acid. The 
action of Δ-6 desaturase is a rate-limiting step in each pathway, with preference for the n-3 
substrate of ALA. If enough precursor is available, this could shift production to n-3 pathway 
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production (Bezard et al., 1994). Following desaturase activity, elongation is the next step in 
each pathway, converting GLA and steroidonic acid into dihomo-gamma-linolenic acid (DGLA) 
and eicosatetraenoic acid (ETA), respectively. These intermediaries undergo further desaturation 
by Δ-5 desaturase which converts DGLA to arachidonic acid (AA) and ETA to eicosapentaenoic 
acid (EPA) in the n-3 and n-6 pathways, respectively. An additional desaturation and elongation 
step converts EPA to docosahexaenoic acid (DHA) through decosapentaenoic acid (DPA) as an 
intermediary. 
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Figure 3.1 Essential fatty acid conversion pathway (adapted from Bezard et al., 1994) 
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 FA Sources 
Because LA and ALA cannot be synthesized by mammals, they must consume these fatty 
acids in their diet. Fresh forage, animal fat, nuts, and seeds such as flaxseed and linseed are 
common sources of ALA (Mueller and Talbert., 1988). Oils such as corn, sunflower, peanut, and 
soy oils contain high levels of LA (Carlier et al., 1991). Although not considered essential, EPA 
and DHA are physiologically important fatty acids as well, and while ALA can be converted to 
EPA and DHA, the conversion rate is unknown in the horse. In humans, the conversion rate is 
low (Larsson et al., 2004), indicating a need for direct supplementation of EPA and DHA. 
Sources high in EPA and DHA include marine species of fish (Mueller and Talbert., 1988) and 
to a lesser degree, plant sources such as algae (Doughman et al., 2007). By directly 
supplementing EPA and DHA, these n-3 FAs can be more rapidly incorporated into plasma and 
tissue by eliminating the rate-limiting step involving the desaturase enzymes in the conversion of 
ALA to EPA and DHA (King et al., 2008, O’Connor-Robinson, 2009).  
 FA Ratios 
Research has focused not only on dietary inclusion of n-3 and n-6 fatty acids but also on 
their ratio because of their treatment effects on PUFA metabolites that influence pro and anti-
inflammatory status in an animal. Humans typically consume a diet high in n-6 and low in n-3 
FAs, resulting in diets that have a high n-6:n-3 ratio. Recommended ratios for human diets range 
from 4-10:1 (Albertazzi and Coupland, 2002). Horses typically consume a forage-based diet low 
in total fat but greater in n-6 FAs; however, the ratio of a typical horse diet consuming fresh 
forage is approximately 4:1 and is still within the recommended range for humans (O’Connor-
Robinson, 2009). Preserved forage feeding rather than fresh grass has decreased the amount of n-
3 FAs that horses would normally consume, so although the ratio is within recommended limits 
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for humans, these recommendations cannot be extrapolated to the equine. In addition, the relative 
importance of the ratio versus the amount of n-3s consumed by the horse has not been 
determined. 
Early results demonstrated that supplemented EPA and DHA incorporate fairly rapidly 
into the horse’s blood with increases detected in 3 d post-supplementation, reaching peak 
incorporation levels by 7 d (King et al., 2008).  Although incorporation is rapid and a large 
number of commercial feed and supplements containing n-3 FAs are available, there are still no 
current equine feeding recommendations available. Many different supplementation levels have 
been investigated in prior studies, ranging from approximately 10 g of total n-3 to 30 g of EPA 
and DHA each. Due to their popularity and availability, more research is necessary to determine 
roles of specific FAs and the optimum rate of supplementation to address specific objectives.  
 Fatty Acid Effects on Eicosanoids and Inflammation 
Dietary fatty acids will incorporate into the cellular membranes and impact the type of 
eicosanoids produced and used for intracellular signaling. Reproduction and inflammation are 
affected by PUFA metabolism through the role in the formation of arachidonic acid-derived 
eicosanoids, primarily prostaglandins, and their roles in the cyclooxgenase-1 and 
cyclooxygenase-2 pathways (Bagga et al., 2003). When n-3 PUFAs are supplemented in the diet, 
anti-inflammatory 3-series prostaglandins are favored (Abayasekara and Wathes, 1999). This 
process has the potential to have an impact on reproduction, injury, and disease. Other products 
that PUFAs influence that affect inflammation include cytokines, thromboxanes, and 
leukotrienes (Das, 2006). These products can also be anti-inflammatory or pro-inflammatory, 
and which products are produced is dependent upon available PUFA precursors (Patterson and 
Georgel, 2014). Generally, when n-3 PUFAs are more abundant in the diet, production of anti-
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inflammatory products is favored and when n-6 PUFAs are more abundant, pro-inflammatory 
products are preferred.  
Studies have been conducted in many species to determine the effect of n-3 
supplementation on the inflammatory process. In humans, positive effects on patients with 
inflammatory conditions such as rheumatoid arthritis, osteoarthritis (OA), osteoporosis, and 
Crohn’s Disease have been documented (Simopoulos, 1991). In addition, EPA improved the 
inhibition of cytokine formation and decreased pro-inflammatory adhesion molecules and 
degrading enzymes in patients with clinical rheumatoid arthritis (Adam, 2003). 
The main focus in equine research are the potential benefits to horses with OA (Manhart 
et al., 2009). Factors involved in the inflammatory process that are typically assessed following 
supplementation are eicosanoids, primarily prostaglandins, cytokines, and leukotrienes. Hall et 
al. (2004) found that n-3 supplementation to healthy adult horses modulated the leukotriene B 
(LTB) inflammatory response. Fish oil supplementation greatly increased LTB5 and increased 
LTB4 as well. In horses with clinical OA, EPA and DHA supplementation decreased the 
synovial fluid white blood cell count and plasma PGE2 concentrations when compared with 
controls (Hall et al., 2004). Plasma fibrinogen was also significantly decreased when analyzed 
from 30 d to 90 d after initiation of the treatment diet. Gibson et al. (1996) showed that horses 
with clinical OA had increased levels of PGE2 within the synovial fluid but no differences in 
PGF2α or LTB4. These data indicate the importance of PGE2 as a potent mediator of 
inflammation and its usefulness as a measurement of joint disease and inflammation. When n-3 
FAs are supplemented, preference for downstream metabolism through the n-3 pathway is 
preferred (Bezard et al., 1994); therefore, supplementation of n-3 FAs can impact this 
inflammatory mediator by shifting production from the n-6 pathway to n-3 products.  
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Supplementation of n-3 FAs has also been shown to decrease in vitro TNF-α, an important 
cytokine involved in the induction of inflammation (McCann et al., 2000; Dinnetz, 2009).  
Circulating and synovial fluid concentrations of inflammatory mediators have been 
shown to be useful in determining the inflammatory status in the horse and these mediators can 
be affected by supplementation of n-3 FAs. While a normal young, growing horse may not 
experience a negative inflammatory status, there are several instances where inflammatory 
mediation may be necessary and useful. Young horses that are overfed or grow too rapidly may 
experience developmental orthopedic diseases (DODs) or epiphysitis associated with increased 
inflammation. Common medical treatments for these conditions involve invasive intra-articular 
steroid injections, long term administration of non-steroidal anti-inflammatory drugs (NSAIDs) 
and possibly invasive arthroscopic surgery (Sirin and Alkan, 2010). Long-term administration of 
NSAIDs may cause gastrointestinal issues, renal toxicity and inhibit healthy bone metabolism, 
potentially by altering prostaglandin synthesis that leads to uncoordinated bone healing (Knych, 
2017); therefore, mitigation and/or prevention of inflammation in these instances would be 
useful.  Dietary supplementation of n-3 FAs could potentially have a protective and beneficial 
effect on the young fast-growing, horse fed to exceed nutritional requirements.  
 Benefits of General Fat Supplementation on Reproduction 
Positive effects of general fat supplementation on reproduction are well-documented in 
numerous species. In cattle, increased fat consumption has been linked to improved follicular 
dynamics (Hightshoe et al., 1991), shorter post-partum intervals before a return to estrus and 
increased conception rates (Mattos et al., 2002), and altered milk composition (Ashes et al., 
1992). Supplemental fat has also been shown to increase circulating P4 (Staples et al., 1998) and 
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improve maternal recognition of pregnancy (Mattos et al., 2000) and embryo quality (Cerri et 
al.,2004).  
Direct supplementation of PUFAs has also been shown to have positive effects in other 
species. Supplementation of n-3 FAs decreased circulating PGF2α (Mattos et al., 2004) and n-6 
supplementation decreased circulating PGF2α (Cullens et al., 2004). Supplementation of n-6 FAs 
also decreased incidences of retained placentas, metritis and mastitis (Cullens et al., 2004). 
Supplementation of PUFAs increased follicle development postpartum and increased follicle size 
at ovulation (Lucy et al., 1993) which has been observed to hasten the first postpartum ovulation 
(Beam and Butler, 1997). In pigs, n-3 supplementation altered PUFA concentrations in the 
uterus, placenta and developing fetus (Brazle et al., 2009) and improved conceptus and piglet 
survival (Rooke et al.,2001). Positive effects of supplemental individual n-3s have also been 
indicated on reproduction in many species.  
A previous study demonstrated that when mares were supplemented with additional fat 
during gestation and lactation, blood lipids were increased in the mare and foal, milk fat was 
increased, and foals had a higher rate of gain (Davidson et al., 1991). In addition, the authors 
found that there was a shorter postpartum interval to ovulation and a decreased number of cycles 
to conception (Davidson et al., 1991). Supplementation of n-3s has also been studied in the mare. 
Maternal DHA and EPA lengthened the postpartum interval to the first ovulation and increased 
the amount of time from development of a 35 mm follicle to ovulation during the first 
postpartum estrous cycle (Poland, 2006). These results of a longer postpartum interval to 
ovulation conflict with results reported by Davidson et al. (1991). A shorter postpartum interval 
to ovulation could have been attributed to differences in addition of fat in general vs. specific 
fatty acid supplementation of the Poland experiment. Schmidt et al. (2010) saw a decrease in the 
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amount of IGF-1 in the follicular fluid of n-3 supplemented mares around ovulation which the 
authors indicated might be responsible for the delayed interval to ovulation in the DHA and EPA 
supplemented mares. Improved endometrial scores and altered gene expression in the developing 
embryo following maternal n-3 supplementation in the mare indicates a positive effect on uterine 
environment and a possible mechanism for increased embryo survivability (Jacobs et al., 2015). 
Supplementation of n-3 FAs has also been shown to decrease the incidence of post-breeding 
endometritis (Brendemuehl et al., 2014).  Supplementation of n-3 FAs can have an effect on a 
wide variety of reproductive areas and more investigation is needed to determine the role of n-3 
supplementation in the postpartum mare and effects on the reproductive process.   
 Fatty Acid Supplementation Effects on Immunity 
Research has shown that n-3 FAs incorporate into many different tissues and secretions, 
such as erythrocytes, muscle, and milk, and in the mare can be passed to the developing foal in 
utero and through suckling (Vineyard et al., 2010, Kruglik et al., 2005). There are a small 
number of studies examining the immunological effect of n-3 FA supplementation in the 
developing foal (Hodge et al., 2017, Kruglik et al., 2005, Duvaux-Ponter et al., 2004). 
Supplementation of n-3s has been shown to affect immunity; however, conflicting results 
indicate a need for further investigation. In healthy adult horses receiving n-3 supplementation, 
PGE2, which is a potent mediator of inflammation, both decreased (Hall et al., 2004) and 
remained unchanged (Vineyard et al., 2010) in response to an immunological challenge.  
Passive transfer of immunity is defined as the transfer of antibodies across the gut in the 
early neonatal period following the birth of the foal. Acquisition of humoral immunity is 
measured by the transfer of immunoglobulins from the dam to the foal through the milk (Jeffcott, 
1972). Because of the characteristics of the mare’s epitheliochoral placenta, immunoglobulins 
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cannot be transferred across the placenta. Immunoglobulins are large molecules that can only be 
absorbed intact for a short period of time, up to 24 h, in the foal’s digestive tract (Galan et al., 
1986). Humoral immunity is measured by IgG concentrations in the foal’s blood and can be used 
to evaluate the success or failure of passive transfer. Humoral immunity is measured by IgG 
concentrations in the foal because it is an abundant immunoglobulin in the horse and has a high 
prevalence in colostrum and blood (Sheoran et al., 2000). 
The results of the effect of n-3 FA supplementation on antibody production in the mare 
and subsequent milk secretions have been conflicting. Kruglik et al. (2005) reported higher IgG 
concentrations in colostrum at parturition from mares supplemented with EPA and DHA; 
however, no affect was seen at 12 or 24 h postpartum and no difference in foal serum IgG 
concentrations were detected at any time point. Stelzini et al. (2006) reported altered FA 
composition in milk and also mare and foal serum, but found that neither fish oil nor flax 
supplementation affected colostrum, milk, or foal IgG concentrations.  In an additional study, 
Poland et al. (2006) found that there was no difference in IgG at parturition between mares 
supplemented with DHA alone, EPA and DHA, or corn oil. Possible differences in results could 
be due to supplementation length, amount of supplementation and IgG subtypes measured. The 
conflicting data suggest a need for further evaluation of the effects of n-3 supplementation on 
IgG production and transfer from the mare to foal.   
 Fatty Acid Effects on Bone Metabolism and Density 
In healthy bone metabolism, there is a constant cycle of bone formation and resorption. 
Osteoblast cells are responsible for bone synthesis, while osteoclasts are responsible for bone 
resorption. Both processes are necessary for natural bone turnover; however, problems such as 
DODs can occur when bone resorption is greater than bone synthesis (Watkins et al., 2001). 
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Synthesis and absorption are measured and evaluated in the live subject through the use of 
various markers coinciding with bone metabolites.  
Several markers, such as osteocalcin (OC) and bone-specific alkaline phosphatase (BAP), 
are used for the measurement of bone synthesis. Osteocalcin is produced by osteoblasts and 
released into systemic circulation, making it a useful noninvasive marker of bone metabolism 
(Lian and Gundberg, 1988). Concentrations of BAP can be a marker for bone formation and 
elevated activity may indicate bone disorders (Gomez et al., 1995). Telopeptides, such as n-
telopeptides (nTX), cross‐linked carboxyterminal telopeptide of type I collagen (ICTP) and C‐
terminal crosslinked telopeptide of type I collagen (CTX) are collagen fragments generated by 
bone resorption and concentrations in the blood can be useful indicators of increased bone 
turnover (Garnero, 2009). Another metabolite used to measure bone turnover is osteoprotegerin 
(OPG), which is a soluble cytokine produced by osteoblasts, and its associated tumor necrosis 
factor receptor (RANKL) that inhibits osteoclastogenesis (Yasuda et al., 1998).  Bone mineral 
content (BMC) and bone mineral density (BMD) may also be useful measurements to determine 
bone health. Studies have evaluated these different markers of synthesis and resorption and the 
impact on these markers by certain factors such as n-3 supplementation.  
Research in humans, animals, and in in vitro studies have shown promising results on the 
beneficial effects of n-3 supplementation and its relationship to improved bone health. Griel et al. 
(2007) reported a significant reduction in n-telopeptides (NTx), a marker of bone turnover, 
following an increase in ALA in the diet of human subjects. The concentrations of NTx were 
positively correlated with the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in all 
diets. In addition, BAP was not altered by increases in n-3 or n-6 supplementation. These results 
indicated bone synthesis was not altered by diet and that inflammatory cytokine expression was 
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correlated with increased bone turnover. Martin-Bautista et al. (2010) found that adult plasma 
FAs were increased after a year of supplementation with fortified milk enriched with EPA, DHA, 
and oleic acid. There were also significant increases in OC, OPG, RANKL, and OPG/RANKL. 
The OPG/RANKL ratio in bone is an important indicator of bone mass (Boyce and Wing, 2007). 
These data indicated there was increased bone synthesis, which conflicted with previous reports 
of no differences in bone synthesis (Griel et al., 2007) coupled with increased bone turnover 
following n-3 supplementation. 
Increasing bone health and strength is an important welfare and economic concern in the 
poultry industry. Tarlton et al. (2013) found that supplementation of ALA via flaxseed provided 
in an ad libitum feed to laying hens decreased keel bone breakage, while increasing BMC, BMD, 
total bone volume, and trabecular bone volume. In contrast, Baird et al. (2007) saw no difference 
in bone characteristics when laying hens were supplemented with flaxseed formulated to provide 
differing ratios of n-6 to n-3 FAs.  
A study in neonatal piglets, which were either low birth weight or very low birth weight, 
demonstrated that supplementation with AA and DHA increased BMC in the spine of low birth 
weight piglets and total BMC in very low birth weight piglets (Kohut et al., 2009). In addition, 
both weight groups showed a decrease in bone resorption related to control diets, whereas bone 
formation was unchanged. In a similar study in normal birth weight neonatal piglets fed at either 
a high or low supplementation level of AA and DHA, whole body and lumbar spine BMD was 
greater in the low group (Mollard et al., 2005). The low group also had decreased concentrations 
of NTx when compared with the high group and unsupplemented controls. Plasma OC and IGF-
1, and ex vivo release of PGE2 from the tibia were not different between groups (Mollard et al., 
2005). The authors concluded low levels of supplementation provided a beneficial effect that was 
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not seen with higher levels. Positive effects at low levels of supplementation not seen at higher 
doses indicates an optimum level of supplementation may exist. Mollard and Weiler (2007) also 
reported that dietary AA and DHA decreased bone resorption but did not alter the circadian 
rhythm of bone turnover markers, NTx and OC in piglets. These results indicate positive effects 
of n-3 supplementation on bone health in neonatal and growing piglets. 
Many studies have also used the mouse and rat as models for bone research. Bonnet and 
Ferrari (2010) supplemented mice with either EPA or DHA from 3 to 17 mo of age and 
determined that EPA and DHA increased trabecular bone volume at 8 mo of age. Supplementing 
EPA alone also improved cortical bone volume and thickness, reduced the age-related decline of 
OC, and increased circulating concentrations of IGF-1. Both the EPA and DHA diet increased 
serum leptin concentrations (Bonnet and Ferarri, 2010). Shen et al. (2006) supplemented adult 
male rats with either menhaden oil (n-3) or safflower oil (n-6). The n-3 supplemented group had 
the greatest BMC and cortical and subcortical BMD and also showed an increase in serum IGF-
1, parathyroid hormone (PTH), vitamin D, and BAP. In addition, the n-3 group had decreased 
bone nitric oxide (NO) production and urinary calcium. The n-6 supplemented group had 
increased bone PGE2 and serum pyrodinoline. These results indicate the n-3 group had greater 
bone density and increased bone synthesis when compared with the n-6 group, which had 
increased bone resorption.  
In growing female rats, dietary DHA has been shown to increase tibia BMD, BMC, and 
decrease lipid peroxidation (Lukas et al., 2011). In addition, supplemented ALA increased serum 
OC concentrations, indicating positive effects of DHA on bone density and positive effects of 
ALA on bone synthesis (Lukas et al., 2011). Lau et al. (2009) supplemented LA to fat-1 mice 
that convert n-6 fatty acids to n-3 FAs. Twelve wk after initiating supplementation, femur n-3 
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concentrations were greater. They found that the high n-6:n-3 negatively correlated with BMC, 
and supplemented EPA and DHA positively correlated with BMC and peak load.  
Maternal FA supplementation during gestation and/or lactation has also been shown to 
affect offspring bone formation. Li et al. (2010) supplemented artificially generated n-3 deficient 
mice pups that were separated from their dam at 2 d of age with either LA, LA and DHA, DPA, 
or DHA and DPA. Offspring at adulthood that were supplemented with DPA had decreased 
BMC and BMD. They found that DHA and total n-3 PUFAs strongly correlated to a positive 
increase in BMC. When rat dams were supplemented with AA and DHA during lactation, their 
offspring had enhanced spine BMC, tibia BMC and BMD, and whole body BMD as well as 
decreased OC. The rat dams had a decrease in the loss of whole body BMC and increased OC 
concentrations, indicating that n-3 supplementation enhanced bone density in the offspring while 
simultaneously protecting the dams from bone loss (Li et al., 2010). In a similar study, Fong et 
al. (2012) found that when rat dams were supplemented with DHA during pregnancy and 
lactation, their offspring had higher resting zone thickness at 3 wk of age. The resting zone is the 
innermost layer of the growth plate at the end of long bones (Abad et al., 2002). Male offspring 
also had an increased bone trabecular number at 3 wk as well as increased bone volume, 
increased osteoblast and decreased osteoclast numbers. In addition, expression of TNF-α, NFκB, 
and IL-6 were decreased in male offspring at 3 wk. No differences were detected beyond the 3 
wk sampling period; however, rat pups were weaned onto rat chow that did not contain 
supplemental DHA. The authors summarized that perinatal DHA increased bone formation and 
resorption and increased bone mass in male, but not female offspring, and the beneficial 
improvements in bone health were not likely to continue into adulthood without continued 
supplementation (Fong et al., 2012). The authors also proposed a possible sex hormone effect on 
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the n-3 FA conversion and incorporation and its effects on subsequent metabolism that affected 
the bone changes. In another comparable study, rat dams were fed n-3, n-3 + n-6, or n-6 enriched 
diets. The n-3 + n-6 supplemented group had increased femur length and increased cortical cross 
section area and BMC of the rat dams (Korotkova et al., 2004). The authors proposed a 
beneficial effect of consuming a variety of different FAs. In the murine model, n-3 
supplementation appears to influence markers of bone synthesis and remodeling and positively 
affect bone density and strength. Differences in results may be due to difference levels and 
lengths of supplementation. Although positive bone changes can be seen with n-3 
supplementation, more research is needed to determine the optimal FAs that generate the greatest 
positive benefit and if these positive results can be replicated in non-murine species. 
 Although many studies evaluating the effects of n-3 FA supplementation on bone health 
and density have been conducted in other species, limited literature exists assessing these effects 
in the horse. No studies were identified investigating the effects of maternal periparturient 
supplementation and subsequent impact on the foal. Other traits, such as age and general 
nutrition in young, growing horses with and without history of DODs, have been investigated to 
assess their effects on bone health. When weanling horses were fed rations at a rate exceeding 
NRC recommendations, body weight and long bone growth was accelerated, possibly at the 
expense of skeletal development (Thompson et al., 1988).  Excess dietary energy in growing 
horses has been shown to lead to an increased incidence of DODs (Glade and Belling, 1984). 
More research is necessary to determine if the positive effects of n-3 FAs, and more specifically 
EPA and DHA, can be observed in bone metabolism of the neonatal foal following maternal 
supplementation, especially those fed to exceed NRC requirements for moderate growth rates. 
An initial determination of whether supplementation can alter the measurements of bone health 
63 
in normal, healthy foals would provide a rationale for further investigation of a possible 
protective effect.  
 Summary 
Supplementation of n-3 FAs has been demonstrated to alter circulating plasma FA 
profiles in the mare and foal.  Positive effects on the reproductive traits of the mare have also 
been observed. In other species, addition of n-3s to the diet have had a positive impact on bone 
metabolism. Further research is necessary to determine if maternal supplementation of n-3 FAs 
during gestation and lactation impacts bone metabolism in the neonatal foal fed to meet their 
requirements.   
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Chapter 4 - Peripartum maternal DHA/EPA supplementation and 
reproductive traits in mares and foal bone metabolism 
 Abstract 
Existing research is limited on foal bone health after peri-partum maternal 
supplementation of n-3 fatty acids. The objectives of the current research were to investigate the 
effect of maternal n-3 fatty acid supplementation on neonatal bone metabolism and mare 
reproductive traits. For this experiment, 17 pregnant stock-type mares were blocked by age, 
parity, and expected foaling date (EFD) and assigned randomly to either of two treatment diets: 
Control (CON; n=8, concentrate with no fat supplementation) or fat-supplemented (FS; n=9, 
concentrate supplemented with Gromega™; providing 13.475 g EPA/11.162 g DHA /d). 
Treatment began 8 wk before EFD. Blood collection for plasma fatty acid analysis began at 
treatment initiation and continued bi-weekly. Additional daily blood sampling from mares began 
once a 30-mm follicle was first detected post-foaling and continued until 5 d post-ovulation. 
Samples were analyzed for progesterone (P4) and insulin-like growth factor-1 (IGF-1). Mares 
were monitored by ultrasound beginning on d 4 and continued until ovulation was detected. Foal 
blood collection occurred at birth and weekly for 8 wk for later fatty acid and bone metabolite 
analyses. At 2 and 4 wk of age, synovial fluid (SF) was collected via arthrocentesis from the 
tarsotibial joint of each foal. Synovial fluid and plasma were evaluated for osteocalcin (OC), 
prostaglandin E2 (PGE2), and carboxyterminal telopeptide of type 1 collagen (ICTP). Synovial 
fluid samples also underwent simple cytological analyses. The study concluded for mares and 
foals at 8 wk. Data were analyzed as a repeated measures design using PROC MIXED of SAS. 
Plasma DHA and EPA concentrations were increased (P<0.05) in the mares and foals. Mare 
gestation length, concentrations of IGF-1 and P4, and postpartum interval to ovulation were 
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similar (P>0.05) between treatments. In addition, no differences were detected in foal plasma 
metabolites or SF PGE2, or OC. The ICTP in SF was greater (P<0.05) in the FS treatment at wk 
4 and SF total protein was greater (P<0.05) at both time points in FS foals. A correlation (r = 
0.49) was detected (P<0.05) between concentration of SF and plasma ICTP. Maternal n-3 
supplementation did not affect mare reproductive traits and had a minimal effect on markers of 
foal bone metabolism in healthy foals fed to meet their growth requirements.  
Keywords: mare, foal, n-3 supplementation, bone metabolism 
 Introduction 
Horses are monogastric herbivores that are naturally designed to consume forage that is 
high in fiber and low in digestible energy. Domestication has altered basic feeding principles of 
horses by including meal feeding and the addition of concentrates. Horses are unable to tolerate 
large amounts of carbohydrates, which are fairly common in conventional concentrate rations. In 
contrast, horses are able to tolerate large amounts of fat, which provides a calorie-dense ration 
without the associated complications of feeding a high energy ration consisting of carbohydrates 
(Bush et al., 2001; Lewis, 2005). Inclusion of fat in the diet has become a common horse 
industry practice and research has been conducted to determine the effects of dietary fat 
supplementation on many different classifications of horses, such as horses in hard work and 
breeding animals. Positive benefits for the horse in general, and more specifically for 
reproductive performance, have been seen with the inclusion of additional fat in the diet 
(Davison et al., 1991). More current research has investigated the effects of specific types of fat, 
in the form of polyunsaturated fatty acids (PUFAs). The omega-3 PUFA (n-3) and omega-6 
PUFA (n-6), and their relative ratio, have been the focus of numerous studies related to growth, 
reproduction, and performance in the horse.  
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Because of the inefficient conversion of linoleic acid (LA) and α-linolenic acid (ALA) 
through the n-6 and n-3 pathways, respectively, the two n-3 fatty acids of primary interest are 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Direct supplementation of EPA 
and DHA allows for more rapid incorporation into plasma and tissue by eliminating the rate-
limiting step in the conversion ALA to EPA and DHA (King et al., 2008; O’Connor-Robinson, 
2009). Supplemented EPA and DHA incorporate fairly rapidly into the horse’s blood and their 
concentrations can be detected in 3 d, reaching peak incorporation levels by 7 d (King et al., 
2008). 
Dietary supplementation with n-3 fatty acids has been shown to impact steroidogenesis, 
oocyte development, and implantation in several species (Wathes et al., 2007). In the horse, n-3 
supplementation lengthened the postpartum interval to ovulation and increased the amount of 
time from development of a 35-mm follicle to ovulation (Kouba et al., 2019). Concentration of 
insulin-like growth factor-1 (IGF-1) in the follicular fluid decreases in n-3 supplemented mares 
around ovulation (Schmidt et al., 2010). In mares supplemented with n-3 fatty acids, increases in 
estradiol-17β (E2) and progesterone (P4), as well as increased follicle and subsequent CL size 
and increased growth of the embryonic vesicle and embryo proper have been reported (Ravi et 
al., 2014).  
In healthy bone metabolism, a constant cycle of bone remodeling occurs. Studies have 
evaluated different markers of synthesis and resorption of bone, and the impact on these markers 
after n-3 supplementation. Research in humans, animals, and also in vitro have shown promising 
results on the beneficial effects of n-3 supplementation with regard to improved bone health in 
adults and juveniles (Kajarabille et al., 2013, Lau et al., 2013). In humans, n-3 fatty acid 
supplementation reduced markers of bone turnover (Griehl et al., 2007) and increased plasma 
67 
fatty acids and synthesis and turnover of bone (Martin-Bautista et al., 2010). In livestock, 
supplementation of flaxseed (providing increased ALA) provided ad libitum in feed to laying 
hens decreased keel bone breakage, while increasing bone mineral content (BMC), bone mineral 
density (BMD), total bone volume, and trabecular bone volume (Tarleton et al., 2013). In 
addition, arachidonic acid (AA) supplemented to low birthweight piglets increased BMC in the 
spine, total BMC and decreased bone resorption (Kohut et al., 2009).  Normal birth weight 
neonatal piglets fed small amounts of AA had greater whole body and lumbar spine BMD and 
decreased bone turnover markers (Mollard et al., 2005). Dietary AA and DHA decreased bone 
resorption but did not alter the circadian rhythm of bone turnover markers in pigs (Mollard and 
Weiler 2007).  
Maternal supplementation during gestation, lactation, or both, also has been shown to 
affect offspring bone formation. Li et al. (2010) supplemented artificially-generated n-3 deficient 
mice pups that were separated from their dam at 2 d of age with LA, LA and DHA, 
docosapentaenoic acid (DPA), or DHA and DPA. As adults, the offspring that were 
supplemented with DPA had decreased BMC and BMD. They found that DHA and total n-3 
PUFAs strongly correlated to a positive increase in BMC. When rat dams were supplemented 
with AA and DHA during lactation, their offspring had enhanced spine BMC, tibia BMC and 
BMD, and whole body BMD as well as decreased OC. The rat dams had a decrease in the loss of 
whole body BMC and increased OC concentrations, indicating that n-3 supplementation 
enhanced bone density in the offspring while simultaneously protecting the dams from bone loss 
(Li et al., 2010). In a similar study, Fong et al. (2012) found that when rat dams were 
supplemented with DHA during pregnancy and lactation, their offspring had higher resting zone 
(innermost layer of the growth plate) thickness at 3 wk of age. Male offspring also had an 
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increased bone trabecular number at 3 wk as well as increased bone volume, increased osteoblast 
and decreased osteoclast numbers. In addition, expression of TNF-α, NFκB, and IL-6 were 
decreased in male offspring at 3 wk. No differences were detected beyond the 3 wk sampling 
period; however, rat pups were weaned onto rat chow that did not contain supplemental DHA. 
The authors summarized that perinatal DHA increased formation and resorption of bone and 
increased bone mass in male, but not female offspring. The beneficial improvements in bone 
health were not likely to continue into adulthood without continued supplementation. The 
authors also proposed a possible sex hormone effect on the n-3 fatty acid conversion and 
incorporation and its effects on subsequent metabolism that affected bone changes (Fong et al., 
2012).  
In another similar study, rat dams were fed n-3, n-3 and n-6, or n-6 enriched diets 
(Korotkova et al., 2004). The n-3 and n-6 supplemented rats had increased femur length and 
increased cortical cross section area and BMC. The authors proposed a beneficial effect of 
consuming a variety of different fatty acids (Korotkova et al., 2004).  
 Although numerous studies evaluating the effects of n-3 FA supplementation on bone 
health and density have been conducted in other species, no current literature exists assessing 
these effects in the horse, especially maternal peri-parturient supplementation. Effects of age and 
general nutrition on bone health and related developmental traits in the young, growing horse are 
well-documented (McIlwraith, 2004). When weanling horses were fed rations at a rate exceeding 
NRC recommendations, body weight and long bone growth was accelerated, possibly at the 
expense of skeletal development (Thompson et al., 1988).  Excess dietary energy in growing 
horses has been shown to lead to an increased incidence of developmental orthopedic diseases 
(DODs) in growing horses (Glade and Belling, 1984).  
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Studies have shown n-3 supplementation impacts reproductive function in the mare and 
that n-3 supplementation may have an impact on bone metabolism in many species. More 
research is necessary to determine effects of n-3 fatty acids, and more specifically EPA and 
DHA, on bone metabolism in the neonatal foal after maternal supplementation. The objective of 
the current study was to determine if maternal DHA/EPA supplementation during late gestation 
and early lactation would alter reproductive traits in the mare. The second objective was to 
determine if supplementation would affect bone metabolism markers for bone synthesis and 
resorption in the healthy, normal foal, which may indicate a protective effect is possible in 
accelerated foal growth.   
 Materials and Methods 
The current experiment was reviewed and approved by Kansas State University 
Institution Animal Care and Use Committee. 
 Animals and Treatments 
Seventeen pregnant, stock-type mares and their resulting offspring were enrolled in this 
study. The mares ranged in age from 4 to 15 yr, weighed an average 541.7 ± 38.1 kg, and were 
categorized as either primiparous or multiparous. Treatment diets were initiated 8 wk before the 
expected foaling date (EFD). Four wk before the EFD, each mare was administered pre-foaling 
vaccinations and a broad spectrum anthelmintic. Mares were group-housed in 3 to 5 acre lots 
with some grass cover and ad libitum access to fresh water and a trace mineral supplement. 
Alfalfa hay was group-fed based on aggregate weight, and a concentrate (Horseman’s Edge®, 
Purina Mills, St. Louis, MO) was fed individually in a 3 m by 3 m enclosure to ensure each mare 
had restricted access to individual portions. Diets were formulated to meet or exceed NRC 
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(2007) requirements for mares in late gestation and early lactation. Proximate analysis of the 
supplement and the fatty acid profile of the feedstuffs and supplement are provided (Table 4.1). 
 
 
 
 
 
Table 4.1 Chemical analysis and fatty acid composition (expressed as % of total fat) of feedstuffs 
and on eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) supplement fed to mares 
during late gestation and early lactation. 
 Feedstuffsa,b 
Itema Concentrate Alfalfa Hay Supplementc 
DM, % 88.09 90.21 98.41 
Crude Protein, % 13.9 18.57 0.73 
ADF, % 10.31 33.23 13.24 
NDF, % 23.21 41.97 16.03 
Fat, % 6.07 2.59 39.20 
Ash, %    
Ca, % 1.40 1.40 7.87 
P, % 0.59 0.27 0.00 
K, % 0.91 2.89 0.00 
DE (Mcal/lb) 1.53 1.24 1.67 
    
Total n-6: 49.89 19.88 1.56 
Linoleic acid 49.89 19.88 1.56 
Arachidonic acid 0.00 0.00 0.00 
    
Total n-3: 5.37 22.99 29.03 
Alpha-linolenic acid 5.35 22.66 1.43 
EPA 0.02 0.00 13.75 
Docosapentaenoic acid 0.00 0.00 2.46 
DHA 0.00 0.33 11.39 
    
n-6:n-3 ratio 9.29 0.87 0.05 
aValues listed as means. 
bCalculated on a DM basis by SDK Laboratories, Hutchinson, KS. 
cPercentage total fat as reported by JBS United, Sheridan, IN. 
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Mares were blocked by EFD and assigned randomly within blocks to either of two 
treatment diets: (1) control (CON, n = 8) consisting of a concentrate (Horseman’s Edge®, Purina 
Mills, St. Louis, MO) with no additional fat supplementation and  (2) fat-supplemented diet (FS, 
n = 9) consisting of a concentrate (Horseman’s Edge®, Purina Mills, St. Louis, MO) 
supplemented with 250 g Gromega® (JBS United Feeds, Sheridan, IN), which is a marine-
derived EPA and DHA supplement that provided 13.475 g EPA and 11.162 g DHA per day. 
Diets were formulated to be isocaloric. Mares in the FS treatment began an acclimation period 5 
d before the initiation of the experiment to slowly introduce the supplement into the diet in 50 g 
increments to reduce feed refusal. Before feeding each FS mare, the supplement was measured 
out and top-dressed on the concentrate. A small amount of water, approximately 250 mL, was 
then applied to the feed to bind the powder to the feed and the supplement was mixed thoroughly 
in the concentrate ration.  
Three wk before EFD, mares were monitored for impending parturition by visual 
inspection and mammary secretion testing. Once parturition was imminent, mares were placed in 
foaling stalls and observed for parturition. Following parturition, mares remained in a stall for at 
least 24 h, and then were turned out in a different 3 to 5 acre pasture with other postpartum 
mares. Pre- and postpartum mares were housed separately for the duration of the study. 
Postpartum mares also were fed individually and buckets were hung at an appropriate height to 
prevent foals’ access to the treatment diet. The procedural time line for all mares is included in 
Fig. 4.1. Treatment diets continued through 8 wk postpartum, at which point the study was 
concluded and both mares and foals were removed from the trial.  
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 Fatty Acid and Hormone Metabolite Analyses 
 Mare and Foal Blood Collection and Fatty Acid Analyses  
Blood collection of mares via jugular venipuncture into 10-mL heparin additive 
Vacutainer® tubes began at the initiation of treatment (wk 0) and continued every 2 wk until the 
termination of the study. Following collection, blood samples were centrifuged at 2,500 x g for 
20 min. Plasma aliquots were prepared and stored at -20° C for later analysis.  
Blood sampling of foals via jugular venipuncture occurred at birth and weekly for 8 wk 
following parturition. Two 10-mL samples were obtained into Vacutainer® tubes, one with and 
one without heparin additive. Blood samples collected in serum tubes were allowed to clot at 
room temperature for 30 min while heparin additive tubes were stored at 5° C until 
centrifugation. After clotting was observed in the serum tubes, all blood samples were 
Figure 4.1 Procedural time line for all mares fed a concentrate ration (CON) or a fat-
supplemented diet (FS) 
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centrifuged at 2,500 x g for 20 min. Plasma and serum aliquots were prepared and stored at 20° 
C for future analysis. Plasma fatty acid profiles from these blood samples were determined using 
gas chromatography techniques as described by Poland (2006). The procedural time line for all 
foals is included in Fig. 4.2. 
 
 
 Mare Hormone Analyses 
 Additional daily blood sampling from each mare occurred once a follicle ≥ 30 mm was 
detected post-foaling via ultrasound evaluation, and continued until d 5 post-ovulation. Blood 
was collected via jugular venipuncture into 10-mL Vacutainer® tubes, allowed to clot at room 
temperature for 30 min, then centrifuged at 2,500 x g for 20 min. Serum aliquots were stored at 
20°C for future analyses. Serum samples were analyzed for P4 (DSL-3900 ACTIVE® 
Progesterone Coated-Tube RIA kit, Diagnostic Systems Laboratories, Inc., Webster, TX) and 
IGF-1(DSL-5600 ACTIVE® IGF-1 Coated-Tube IRMA kit, Diagnostic Systems Laboratories, 
Inc., Webster, TX). Intra-assay CV, inter-assay CV, and sensitivity were 5%, 12%, and 2 ng/mL, 
Figure 4.2 Procedural time line of suckling foals of mares fed either a control diet (CON) or a 
fat-supplemented diet (FS) 
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respectively for the IGF-I assay. Assay sensitivity for progesterone was 0.01 ng/mL and the 
intra-assay CV was 8.4%. All assays were previously validated in the equine (Schmidt, 2010).  
 Mare Ovarian Monitoring 
 Ovaries of each mare were monitored by transrectal ultrasonography every other day 
beginning on d 4 postpartum and continuing until the presence of a follicle ≥ 30 mm was first 
detected. Once a follicle ≥ 30 mm was observed, ultrasound frequency increased to once daily 
until ovulation was detected. Ovulation was characterized by the disappearance of the 
preovulatory follicle and subsequent corpus luteum formation. Gestation length and interval from 
foaling to first postpartum ovulation were calculated and the diameter of the follicle at ovulation 
was recorded.  
 Foal Bone Metabolism Markers 
 Plasma Samples  
Foal plasma was analyzed for OC (MicroVue Osteocalcin ELISA Kit, Quidel, San Diego, 
CA) as a bone marker associated with bone synthesis. Plasma also was analyzed for ICTP (UniQ 
ICTP RIA, Orion Diagnostica, Immunodiagnostic Systems Inc, Scottsdale, AZ) as a marker of 
bone remodeling. In addition, concentrations of PGE2 (PGE2 ELISA Kit, ENZO, Farmingdale, 
NY) were analyzed because of its role in the inflammatory process and induction of bone 
resorption. Sensitivity for the plasma PGE2 assay was 19.6 pg/mL and the intra-assay CV was 
3.85%. The plasma OC assay had a sensitivity of 0.85 ng/mL and an intra-assay CV of 5.7%. 
Sensitivity for the plasma ICTP assay was 0.05 µg/L and the intra-assay CV was 8.0%. Assays 
were validated in equine plasma according to manufacturers’ protocols.  
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Synovial Fluid Samples 
At 2 and 4 wk of age, synovial fluid samples were collected via dorsomedial 
arthrocentesis from the tarsotibial joint of each foal’s hock to measure intra-articular 
concentrations of bone markers. Foals in each treatment were selected randomly for the 
arthrocentesis to be performed either on the right or left tarsotibial joint at 2 wk. At 4 wk, the 
same joint was used for that foal. The procedure was conducted under standing anesthesia 
accomplished by administration of xylazine hydrochloride (0.4 to 0.8 mg/kg, IV, Anased®, 
Lloyd, Inc, Shenandoah, IA). Following routine aseptic preparation of the puncture sight on the 
hock, 2 to 4 mL of synovial fluid was obtained via dorsomedial arthrocentesis using a 20 g, 12 
mm needle. Synovial fluid was separated immediately into 2 aliquots and placed on ice. One, 1 
to 2 mL sample was placed in a heparin Vacutainer® tube and submitted to the Kansas State 
University Clinical Pathology Laboratory for cytology analysis of total nucleated cell count 
(TNCC) and total protein (TP). A second 1 to 2 mL aliquot was centrifuged at 450 x g for 5 min 
to remove any cellular contamination that could interfere with future analysis. These synovial 
aliquots were stored at 20°C for future analysis. The synovial fluid was analyzed for OC, PGE2, 
and ICTP as previously described for the plasma analysis.  
Sensitivity for the synovial fluid PGE2 assay was 9.78 pg/mL and the intra-assay CV was 
1.0%. The synovial fluid OC assay had a sensitivity of 0.85 ng/mL and an intra-assay CV of 
8.6%. Sensitivity for the synovial fluid ICTP assay was 0.55 µg/L and the intra-assay CV was 
5.05%. Assays were validated in equine synovial fluid according to manufacturers’ protocols.  
 Statistical Analyses 
A randomized complete block design was used for this study with mares assigned 
independently to the CON or FS treatment within blocks. Repeated measures were analyzed by 
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the MIXED procedure of SAS (Version 9.3, Cary, NC) with treatment, mare within treatment, 
day, and treatment x day included in a split-plot ANOVA. Treatment differences were tested by 
the mare within treatment variance (split-plot error), whereas effects of day and treatment x day 
were tested by the residual error (whole-plot error). Outcome repeated measures included mare 
and foal plasma FA profiles, mare serum IGF-1, P4, and E2 concentrations, and foal serum, 
plasma and synovial fluid bone markers, and foal synovial fluid cytology. Treatment by day 
means were separated within day by least squared differences (LSD). 
Single time point data were analyzed by ANOVA and the model included treatment and 
block. Outcome variables included mare gestation length, interval from foaling to ovulation, and 
follicle diameter before ovulation. All data are presented as least squared means ± SEM and 
significance was determined at a P<0.05.  
 Results 
 Fatty Acids 
 Mare Plasma 
A single mare foaled beyond 2 wk past her EFD. Her plasma FA data was truncated to 16 
wk. Changes in mare plasma FA concentrations were evident during wk 2 after initiation of the 
treatment diets. Concentrations of LA did not differ (P>0.05) between treatments for the majority 
of the experiment, but were greater (P<0.05) in the CON compared with FS mares at 12 and 14 
wk (Fig. 4.3). A significant day effect (P<0.01) was also observed in LA concentrations. 
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Arachidonic acid concentrations were greater (P<0.01) in the FS treatment from wk 2 to 
12, but did not differ (P>0.05) at 14 wk and were again greater in the FS treatment at 16 wk 
(P<0.01; Fig. 4.4). A treatment by day interaction (P=0.003), as well as a treatment (P<0.01) and 
day (P<0.01) effect, were observed in AA concentrations. Concentrations of ALA were 
comparable to LA, as they were similar for the majority of the trial, with a strong trend at wk 12 
(P=0.058) and 14 (P=0.052) for increased concentrations in CON mares (Fig. 4.5). A day effect 
trend (P=0.057) was also detected. 
 
Figure 4.3 Mare plasma linoleic acid (LA) concentrations (LSMeans ± SEM) in response to 
dietary supplementation during late gestation and early lactation with a fish oil-supplemented 
diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 and 10 wk. 
aP<0.05 
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Figure 4.4 Mare plasma arachidonic acid (AA) concentrations (LSMeans ± SEM) in 
response to dietary supplementation during late gestation and early lactation with a fish oil-
supplemented diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 
and 10 wk. aP<0.05, bP<0.01 
 
Figure 4.5 Mare plasma alpha-linolenic acid (ALA) concentrations (LSMeans ± SEM) in 
response to dietary supplementation during late gestation and early lactation with a fish oil-
supplemented diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 
and 10 wk. *Denotes a trend P=0.06. 
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Plasma EPA was greater (P<0.01) in FS mares by wk 2 and remained greater throughout 
the trial compared with CON (Fig. 4.6). A treatment by day interaction (P<0.01), as well as an 
overall treatment (P<0.01) and day (P<0.01) effect, was observed. Plasma DPA was also greater 
(P<0.01) in FS mares compared with CON from 2 wk to 12 wk, similar (P>0.05) at wk 14, and 
again greater (P<0.05) in the FS mares at wk 16 (Fig. 4.7). A significant treatment by day 
interaction (P<0.01), as well as an overall treatment (P<0.01) and a day (P<0.01) effect, was 
observed. 
Serum DHA concentrations were greater (P<0.01) in FS mares from wk 2 to 12 and at wk 
16 (Fig. 4.8). At wk 14, a trend was observed (P=0.061) for greater DHA in FS mares. 
Treatment, day, and treatment by day interactions (P<0.01) were observed.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Mare plasma eicosapentaenoic acid (EPA) concentrations (LSMeans ± SEM) in 
response to dietary supplementation during late gestation and early lactation with a fish oil-
supplemented diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 
and 20 wk.  bP<0.01. 
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Figure 4.7 Mare docosapentaenoic acid (DPA) concentrations (LSMeans ± SEM) in 
response to dietary supplementation during late gestation and early lactation with a fish oil-
supplemented diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 
and 10 wk. aP<0.05, bP<0.01.  
Figure 4.8 Mare plasma docosahexaenoic acid (DHA) concentrations (LSMeans ± SEM) in 
response to dietary supplementation during late gestation and early lactation with a fish oil-
supplemented diet (FS, n = 9) or a control diet (CON, n = 8). Parturition occurred between 8 
and 10 wk. bP<0.01. *Denotes a trend (P=0.06). 
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 Foal Plasma 
Concentrations of LA did not differ (P>0.05) between treatments (Fig. 4.9). A significant 
day effect (P<0.01) was observed in LA concentrations. Arachidonic acid concentrations were 
greater (P<0.05) in FS foals from wk 2 to 8 (Fig. 4.10). A treatment by day interaction was 
detected (P<0.01), as well as a treatment (P<0.01) and day (P<0.05) effect was observed for AA 
concentrations. Concentrations of ALA were variable throughout the study (Fig. 4.11). A trend 
(P=0.055) for greater concentrations at wk 4 and greater concentration (P<0.05) at wk 8 was 
observed in CON foals. A day effect (P<0.01) was also evident.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Foal plasma linoleic acid (LA) concentrations (LSMeans ± SEM) at birth (wk 0) 
and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, n = 8) or 
fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation.  
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Figure 4.10 Foal plasma arachidonic acid (AA) concentrations (LSMeans ± SEM) at birth 
(wk 0) and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, n = 
8) or fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation. 
aP<0.05, bP<0.01. 
 
Figure 4.11 Foal plasma alpha-linolenic acid (ALA) concentrations (LSMeans ± SEM) at 
birth (wk 0) and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, 
n = 8) or fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation. 
aP<0.05. * Denotes a trend (P=0.06). 
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Plasma EPA concentrations were greater (P<0.01) in the FS foals at birth (wk 0) and 
remained greater throughout the experiment compared with CON foals (Fig. 4.12). A treatment 
by day interaction (P<0.01) as well as a treatment (P<0.01) and day (P<0.01) effect were 
observed. Plasma DPA also was elevated (P<0.01) in the FS foals beginning at wk 2 and 
remained greater for the remainder of the experiment (Fig. 4.13). A treatment by day interaction 
was detected (P<0.01) in addition to a treatment (P<0.01) and day (P<0.01) effect. 
Plasma DHA was increased (P<0.01) in FS foals from wk 2 to 4. A trend (P=0.07) was 
observed for greater DHA in FS foals at wk 6 with DHA concentrations again greater (P<0.05) 
by wk 8 (Fig. 4.14). A treatment by day interaction was detected (P<0.01) in addition to a 
treatment (P<0.01) and day (P<0.01) effect.   
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Foal plasma eicosapentaenoic acid (EPA) concentrations (LSMeans ± SEM) at 
birth (wk 0) and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, 
n = 8) or fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation. 
bP<0.05. 
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Figure 4.13 Foal plasma docosapentaenoic acid (DPA) concentrations (LSMeans ± SEM) at 
birth (wk 0) and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, 
n = 8) or fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation. 
bP<0.01. 
 
Figure 4.14 Foal plasma docosahexaenoic acid (DHA) concentrations (LSMeans ± SEM) at 
birth (wk 0) and 2, 4, 6, and 8 wk of age when suckling mares were fed a control diet (CON, 
n = 8) or fish oil-supplemented diet (FS, n = 9) during late gestation and early lactation. 
aP<0.05, bP<0.01. * Denotes a trend (P=0.06). 
 
* 
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 Mare Reproductive Traits 
No differences (P>0.05) were observed in gestation length (346.4 ± 3.7 d for CON mares 
vs. 347.4 ± 3.3 d for FS mares), interval from foaling to initial postpartum ovulation (14.0 ± 2.5 
vs. 17.3 ± 2.3 for CON and FS mares, respectively), or follicle diameter at ovulation (45.7 ± 1.5 
vs. 47.2 ± 1.4 for CON and FS mares, respectively) between the FS and CON mares.  
 Mare Hormone Concentrations 
No differences were detected between treatments for either serum IGF-1 (Fig. 4.15) or P4 
(Fig. 4.16) concentrations during the peri-ovulatory period. As expected, a day effect was 
observed (P<0.01) for both IGF-1 and P4.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Serum insulin-like growth factor-1 (IGF-1) concentrations (LSMeans ± SE) 
during 4 d before first postpartum ovulation (OV), at OV, and on d 3 and 5 post-ovulation 
in mares fed a control diet (CON, n = 8) or a fish oil-supplemented diet (FS, n = 9).  
Days Relative to OV (d 0) 
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 Foal Bone Metabolism Markers 
 Plasma 
No differences (P>0.05) were observed in plasma concentrations of PGE2 (Fig. 4.17), 
ICTP (Fig. 4.18), or OC (Fig. 4.19) between CON and FS foals. Concentrations of OC were less 
(P<0.01) in both treatments at wk 4 compared with wk 2. 
 
 
 
 
Days Relative to OV (d 0) 
Figure 4.16 Serum progesterone concentrations (LSMeans ± SE) during the periovulatory 
period at first postpartum ovulation (d 0) and on d 3 and 5 post-ovulation in mares fed either 
a control diet (CON, n = 8) or fish oil-supplemented diet (FS, n = 9). 
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Figure 4.18 Plasma carboxyterminal telopeptide of type 1 collagen (ICTP) concentrations 
(LSMeans ± SE) at 2 and 4 wk of age in foals suckling mares fed a control (CON,n = 8) or 
fish oil - supplemented (FS, n = 9) diet during late gestation and early lactation.  
Figure 4.17 Plasma prostaglandin E2 (PGE2) concentrations (LSMeans ± SE) at 2 and 4 wk 
of age in foals suckling mares fed a control (CON, n = 8) or fish oil-supplemented (FS, n = 
9) diet during late gestation and early lactation.  
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 Synovial Fluid 
No differences (P>0.05) were found in synovial fluid concentrations of PGE2 (Fig. 4.20) 
or OC (Fig. 4.21) between CON and FS foals. Concentrations of ICTP (Fig. 4.22) were greater 
(P<0.05) in FS foals at wk 4 compared with CON foals and a trend (P = 0.07) was detected for a 
treatment effect on ICTP concentrations in the FS foals.  
 
 
Figure 4.19 Plasma osteocalcin (OC) concentrations (LSMeans ± SE) at 2 and 4 wk of age 
in foals suckling mares fed a control (CON, n = 8) or fish oil- supplemented (FS, n = 9) diet 
during late gestation and early lactation. 
a 
a 
b 
b 
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Figure 4.20 Synovial fluid prostaglandin E2 (PGE2) concentrations (LSMeans ± SE) at 2 
and 4 wk of age in foals suckling mares fed a control (CON, n = 8) or fish oil- 
supplemented (FS, n = 9) diet during late gestation and early lactation.  
Figure 4.21 Synovial fluid osteocalcin (OC) concentrations (LSMeans ± SE) at 2 and 4 wk 
of age in foals suckling mares fed a control (CON, n = 8) or fish oil-supplemented (FS, n = 
9) diet during late gestation and early lactation.   
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 Correlations 
No significant correlations (P>0.05) were detected between concentrations of PGE2 (r = 
0.04) and OC (r = 0.01) in the foal synovial fluid and plasma. A significant correlation (r = 0.49, 
P<0.05) was observed between ICTP concentrations in foal synovial fluid and plasma.  
 
 Synovial Fluid Cytology 
Total protein was greater (P<0.05) in FS foals compared with CON at wk 2 and 4 (Fig. 
4.23). An overall treatment effect (P<0.05) also was observed. No differences or effects (P>0.05) 
were observed in total nucleated cell counts between treatments (Fig. 4.24). 
 
 
 
 
 
a 
b 
Figure 4.22 Synovial fluid carboxyterminal telopeptide of type 1 collagen (ICTP) 
concentrations (LSMeans ± SE) at 2 and 4 wk of age in foals suckling mares fed a control 
(CON, n = 8) or fish oil-supplemented (FS, n = 9) diet during late gestation and early 
lactation. Columns lacking a common superscript differ, P<0.05. 
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Figure 4.23 Synovial fluid total protein concentrations (LSMeans ± SE) at 2 and 4 wk of 
age in foals suckling mares fed a control (CON, n = 8) or fish oil-supplemented (FS, n = 9) 
diet during late gestation and early lactation. Columns within wk lacking a common 
superscript differ, P<0.05. 
Figure 4.24 Synovial fluid total nucleated cell counts (LSMeans ± SE) at 2 and 4 wk of age 
in foals suckling mares fed a control (CON, n = 8) or fish oil-supplemented (FS, n = 9) diet 
during late gestation and early lactation. 
 
 
 
a 
 
a 
b 
b 
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 Discussion 
Plasma FA profiles in the equine have been well-characterized in general and the effects 
of n-3 supplementation on plasma FA concentrations also are well-documented. In this study, 
LA was found to be the most abundant PUFA in circulation, confirming previous studies 
(Bergero et al., 2002). The concentrations of LA were relatively stable and similar between 
treatments for the initial 10 wk of the experiment as well as the 16th and final wk; however, a 
significant increase in plasma LA concentrations was observed in CON mares at wk 12 and 14. 
A similar profile was also observed in mare plasma ALA. These results were expected as mares 
in both treatments were consuming the same diet and no differences in LA, AA and ALA were 
anticipated. By directly supplementing EPA and DHA in FS mares, additional substrate is 
provided for upstream conversion of ALA, AA and LA. Direct supplementation of these PUFAs 
can also decrease enzyme competition for substrate in the rate-limiting steps of upstream 
conversion (Williams and Burdge, 2006). Greater plasma concentrations of ALA and LA in 
CON mares at wk 12 and 14 could be explained by transition of seasonal grasses from dormancy 
into the growing season. Once mares foaled in early spring, they were moved to a different 
pasture that had more high quality smooth bromegrass availability. Mares typically foaled 
around the 8 to 10 wk mark and this could have coincided with increasing availability and new 
growth of forage to which the mares had access. Fresh green forages are a source of n-3 and n-6 
fatty acids (Raes et al., 2004) and consuming fresh grass in addition to their concentrate and hay 
could have provided additional substrates of LA and ALA to the entire group, with the CON 
mares having less enzyme availability for down-stream conversion to EPA and DHA, thus a 
greater concentration of LA and ALA remained in circulation.  
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The effect of n-3 supplementation on plasma AA concentrations is variable in the 
literature. In the current study, AA generally remained greater in FS mares. Although AA is not 
typically a component of the n-3 pathway, previous research in our lab has shown both elevated 
plasma AA concentrations in FS mares (Poland, 2006, Schmidt, 2010) and similar concentrations 
between supplemented and control mares (Kruglik et al., 2005). Other authors have reported 
increased AA concentrations post-supplementation (Hall et al., 2004; King et al., 2008). 
Differences in the effect of supplementation on AA concentrations may be the result of differing 
amounts and duration of supplementation. Although not an efficient conversion, supplemental 
DHA could lead to additional AA production (Raz et al., 1998). In addition, as greater n-3 
substrates are provided, there is a preferential shift in enzyme competition towards n-3 
production and away from n-6 production (Abayasekara and Wathes, 1999). Dietary AA could 
undergo less conversion, and as uptake from target tissue preferentially takes up n-3s, greater 
amounts of AA could be left in circulation. No AA was provided in the concentrate or hay ration 
fed in either diet. Circulating AA could increase because of downstream conversion of LA, or 
the very inefficient process of upstream conversion of EPA and DHA metabolites or it may have 
been consumed in the fresh forage available to all mares. 
Consistent with previous findings, supplementation of EPA and DHA increased plasma 
concentrations of these FAs in FS mares. Conversion of ALA to EPA and subsequently to DHA 
is not well defined in the horse; however, evidence indicates poor conversion rates (Hansen et 
al., 2002), which supports the concept that direct supplementation of EPA and DHA is a more 
efficient way to increase plasma concentrations of these fatty acids than supplementation of 
precursor FAs. King et al. (2008) found increases in plasma EPA and DHA concentrations as 
early as 3 d post-supplementation with peak concentrations at 14 d after initiating 
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supplementation in mares. In the current experiment, significant increases were observed for 
EPA, DPA and DHA by wk 2 of supplementation in FS mares; however, peak concentrations 
were not observed until wk 6 for EPA and DPA and wk 8 for DHA, followed by a gradual 
decline. The initial rise is apparently because of supplementation and the gradual decline in FA 
could have resulted from these FAs being removed from circulation and incorporated into target 
tissues (Vineyard et al., 2010). These mares also foaled during the weeks following peak 
concentrations of these FAs and the decline could be associated with the mobilization of these 
FAs in their milk. Evidence for an effect of maternal dietary n-3 supplementation on milk FA 
composition has been well documented (Kruglik et al., 2005, Stelzini et al., 2006, Kouba et al., 
2019). The FA profiles of the mare’s milk were not characterized in the current study; however, 
previous supplementation research supports increased n-3 FA concentrations in the milk. 
Increases in the foal’s plasma n-3 FA profiles in this study and in previous research (Kruglik et 
al., 2005, Stelzini et al., 2006, Kouba et al., 2019) confirm the transfer of FAs both in utero and 
through the milk. Timing and peak concentrations of EPA and DHA were similar to previous 
reports in our lab using similar rates of supplementation (Schmidt, 2010, Kouba et al., 2019). 
When different supplementation amounts are used, peak concentrations can vary (King et al., 
2008). Results have indicated a threshold level of FA uptake and incorporation into the blood, 
demonstrating the likelihood of an optimal supplementation rate with no further benefit observed 
following greater supplementation rates.  
At birth, foals generally have little to no short and medium chain FAs in plasma, 
indicating these shorter chain FAs might be the preferential energy source for a neonatal foal and 
are taken up in the liver and are not abundant in circulation. Short and medium chain FAs have 
been demonstrated to be the preferential FA source in calves (Hocquette and Bauchart, 1999). 
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Placental transfer of FAs from the mare to the developing conceptus has been demonstrated in 
the horse (Stammers et al., 1987, Duvaux-Ponter et al., 2004). In this study, plasma FA 
concentrations in the foal followed similar trends to those seen in the mare with LA being the 
predominant plasma FA in the FS and CON foals. Similar to mares, foal plasma FA sharply 
increased after birth and was nearly identical between treatments during the 8-wk sampling 
duration. Foal AA concentrations were greater beginning at 2 wk and continued for the duration 
of the trial. Plasma concentrations were devoid of ALA at birth and sharply increased in both 
treatments by 2 wk. Although significant differences were observed at some time points, 
supplementation did not distinctly alter FA patterns or overall differences of ALA 
concentrations.  
Consistent with the previous literature, circulating concentrations of EPA, DPA, and 
DHA were observed in all foals at birth. In FS foals, EPA was greater at birth, consistent with 
previous reports in our lab (Kruglik et al., 2005) and with other research in the foal (Stelzini, 
2006). Blood sampling occurred before the foal suckling, thus FAs present in the foal plasma at 
birth provide evidence for placental transfer of these long–chain fatty acids (LCFAs). 
Concentrations of EPA, DPA, and DHA increased in the 2-wk sampling period following birth, 
confirming previous reports that foals are capable of both digestion and absorption of LCFA 
ingested from their dam’s milk (Stelzini, 2006). Similar to mare plasma FA profiles, plasma 
concentrations of EPA and DHA showed peak concentrations followed by a decreasing trend 
that leveled out by wk 8. These data are consistent with previous reports (Kruglik et al., 2005, 
Stelzini, 2006, Kouba et al., 2019). Of note, although supplemented mares received DHA and 
EPA, DHA did not differ between foal treatments at the initial sampling period but was greater 
in FS foals from 2 wk on. In addition, peak concentrations of both EPA and DHA were greater in 
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FS foals compared with peak concentrations observed in the FS mares. Concentrations of EPA 
and DHA in the mare’s milk have been reported to be concentrated, with values approaching 10 
times the concentration in the plasma. Milk FA composition is not only determined by FA uptake 
from circulation by the mammary cell, but also by de novo FA synthesis in the mammary gland 
(Neville and Picciano 1997). When supplementing equal amounts of EPA and DHA to full-size 
horses and miniature horses, greater concentrations of these FAs are seen in the miniature horses 
(Furtney, 2009) and this could be the result of a smaller blood volume and decreased dilution of 
FA concentrations in circulation. Increased FA concentrations in the foal’s blood may have 
occurred because of the difference in size and blood volume in addition to increased amounts of 
FAs ingested in the milk. 
Previous studies of mare reproductive traits and hormone concentrations following n-3 
supplementation have reported variable effects. In the current experiment, no differences were 
detected in gestation length, interval from foaling to the initial postpartum ovulation, or diameter 
of the follicle near ovulation. Our results contrast previously reported findings that n-3 
supplementation increased the postpartum interval to ovulation in the mare (Poland, 2006). 
Poland (2006) found that n-3 supplemented mares underwent normal follicular growth following 
parturition, but stalled once a follicle > 35 mm was established, and the interval from 
development of a 35-mm follicle to ovulation was increased in the n-3 supplemented treatment. 
The author theorized that either a decrease in the availability of AA as a substrate for PGE2 
might have occurred or decreased IGF-1 in the supplemented group affected ovulation. Both 
PGE2 (Martinez-Bovi and Cuervo-Arango, 2016) and IGF-1 (Donadeu and Pedersen, 2008) play 
crucial roles in follicle maturation and ovulation in the mare. A subsequent study found that 
follicular fluid concentrations of IGF-1 were decreased in mares supplemented with EPA and 
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DHA (Schmidt, 2010). Circulating plasma IGF-1 concentrations did not differ between 
treatments in the current study, but localized IGF-1 within the follicle was not evaluated and may 
have differed.  
Reports of the effects of n-3 supplementation on P4 concentrations are also variable as 
both increases, decreases, and no differences following supplementation have been reported in 
horses and other species (Burke et al.,1997, Heravi- Moussavi et al., 2007). The mechanism for 
supplemental n-3 effect on P4 concentrations is unclear. Increased circulating P4 could be 
attributed to alteration of cholesterol uptake for P4 synthesis (Childs et al., 2008), alteration of 
transcription factors associated with P4 synthesis (Wathes et al., 2007), inhibition of COX-2 and 
increases in steroid acute regulator (STAR) protein (Wang et al., 2003), or simply decreased P4 
clearance from circulation (Hawkins et al., 1995). Schmidt (2010) and Furtney (2009) both found 
increased circulating P4 concentrations in n-3 supplemented mares. In this study, no effect was 
observed on serum P4 concentrations in the mare during the peri-ovulatory period after 8 wk of 
supplementation. Inconsistency in reported effects on P4 concentrations may have resulted from 
a variety of factors including different supplementation amounts and duration, and different 
physiological states of the mares. 
In healthy bone metabolism, there is a constant cycle of bone remodeling conducted by 
osteoblast and osteoclast cells. Bone synthesis and mineralization takes place rapidly after birth 
and then slows more closely to maintenance levels (Zeigler et al., 1974). Both resorption and 
synthesis are necessary for natural bone turnover; however, problems such as DODs can occur 
when bone resorption is greater than bone synthesis (Watkins et al., 2001). Studies investigating 
n-3 supplementation effects on markers of synthesis and resorption have reported promising, 
although variable, results in its relationship to improved bone health (Kajarabille et al., 2013). In 
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humans, n-3 supplementation has been shown to both significantly reduce bone turnover markers 
with no effect on markers of bone synthesis (Griel et al., 2007) and increase bone synthesis while 
increasing bone turnover (Martin-Bautista et al., 2010). Studies in livestock have indicated n-3 
supplementation decreases bone breakage while increasing bone mineral content, density, and 
volume (Tarlton et al., 2013), and decreases markers of bone turnover (Mollard et al., 2005). 
Additional conflicting studies have reported no differences in bone characteristics following 
supplementation (Baird et al., 2007). Supplementation of n-3 FA in the murine model has been 
shown to increase bone synthesis (Shen et al., 2006, Lukas et al., 2011). Following maternal 
supplementation, offspring of n-3 supplemented dams had a strong correlation with increased 
bone mineral content (Li et al., 2010) and increased osteoblast number and decreased osteoclast 
number (Fong et al., 2012).  
To this author’s knowledge, the current experiment is the first to characterize maternal n-
3 supplementation and subsequent effects on foal bone metabolism as measured by plasma and 
synovial fluid markers for bone synthesis and resorption. In contrast with several studies 
conducted in other species, the foal plasma and synovial fluid concentrations of PGE2 and OC 
did not differ between treatments; however, there was a trend for elevated plasma ICTP 
concentrations in FS foals at wk 2 followed by greater concentrations by wk 4. These results are 
similar to a human study that found no changes in bone synthesis markers but increased bone 
resorption markers (Griel et al., 2007). Because retrieval of synovial fluid through joint 
arthrocentesis is an invasive procedure requiring specialized skills, the correlation between 
values of bone metabolites in the synovial fluid and concentrations in plasma were examined to 
determine if analysis of the blood would be an accurate indicator of bone markers in synovial 
fluid. No correlation was detected between PGE2 and OC; however, a significant correlation was 
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observed between ICTP in the blood and synovial fluid, indicating plasma levels of ICTP may 
have limited use as a predictor of synovial fluid values. While significant, the correlation value 
was lower than typically associated with a strong correlation, thus indicating a low diagnostic 
value as a predictive indicator. 
Foal synovial fluid also was submitted for cytological evaluation. Total protein in 
synovial fluid can be a useful measure of joint inflammation and TNCC can be a useful indicator 
of joint infection (Forsyth, 2018). No differences were detected in TNCC either between 
treatments or at different collection time points; however, a significant treatment effect was 
observed when comparing TP between treatments.  The TP was surprisingly greater in foals 
nursing supplemented mares compared with controls. Due to the anti-inflammatory effects of n-3 
supplementation, it was theorized n-3 supplementation would decrease TP in the FS treatment. 
Even though TP in the joint was greater in FS foals, no increases were observed in synovial fluid 
PGE2 concentrations, indicating foals were not in a pro-inflammatory state. Although not 
investigated in the current study, n-3 supplementation has the ability to alter FA composition of 
the synovial fluid in humans (Wu et al., 2017). Although measurement of synovial fluid FA 
profiles would have been useful in the current study, limited sample volume prohibited further 
analysis. The effect of n-3 supplementation on the alteration of FA composition in synovial fluid 
of horses may provide evidence of its ability to alter the inflammatory status within the joint. 
Further investigation into different supplementation levels and amounts and its effect on synovial 
fluid FA composition is warranted. 
Although limited effects of maternal n-3 supplementation on foal bone metabolism 
markers was observed in healthy foals suckling dams fed to meet NRC requirements, further 
research is necessary to elucidate n-3 supplementation’s potential role as a mediator for DODs. 
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Future areas of investigation could include n-3 supplementation effects on foals fed to exceed 
their requirements and grow at an accelerated rate or those predisposed to certain orthopedic 
diseases, either by genetics or injury. Although no supplementation effects were seen in healthy 
foals, it is possible n-3 supplementation could provide a protective effect when DODs were 
induced or bone metabolism was disrupted. Other potential areas for investigation include 
alternate traits and/or diagnostic techniques. In humans, BMD is an important indicator for bone 
strength, particularly when orthopedic diseases such as osteoarthritis (OA) and osteoporosis are 
present (Kaveh et al., 2010). In horses, increasing BMD has been positively correlated with a 
decrease in orthopedic disease and injury (Kobayashi et al., 2007). In foals, BMD rapidly 
increases until 2 yr at which time it plateaus, mirroring a normal growth curve (Yamada et al., 
2015). In other species, research has indicated that n-3 supplementation can affect BMD 
(Tarleton et al., 2013) and measurement of this trait may provide a better picture of supplemental 
n-3 effect on foal bone health. Several diagnostic procedures have been investigated to evaluate 
BMD in horses, including ultrasound (Jeffcott and McCartney, 1985), x-ray (Bowen et al., 
2013), dual energy x-ray absorptiometry (DXA; Vaccaro et al., 2012) and computerized 
tomography (CT; Waite et al., 2000). The DXA and CT analyses are the most widely used and 
reliable indicators of orthopedic disease in humans; however, these procedures require access to 
specialized, expensive equipment in the horse. Although x-ray and ultrasound are relatively 
inexpensive and accessible, measurements from these techniques are more variable and provide 
less beneficial data as short-term changes cannot be observed using these procedures. Further 
research on the effects of n-3 supplementation to a growing foal, with and without DODs, on 
BMD as measured by DXA or CT could provide a more precise picture of the impact on foal 
bone health.  
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 Conclusions 
Supplementation of marine-derived EPA and DHA during late gestation and early 
lactation altered plasma FA concentrations in the mare, as previously reported, and also alters the 
plasma FA concentrations of the in utero and suckling foal. Mare gestation length, interval to 
first postpartum ovulation, and diameter of the dominant follicle at ovulation were not affected 
by n-3 supplementation. Minimal effect, as evidenced by increased SF ICTP in FS foals, was 
observed on bone metabolism markers in healthy foals suckling dams fed to meet their NRC 
requirements. A potential role for supplemental n-3 FAs to improve bone health traits in foals 
experiencing an orthopedic insult cannot be eliminated by the results and warrants further 
investigation as a possible mediator for DODs in the foal.  
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